"idFreq0","PMID","subpopSize","subset1","subset2","subset3","expFrequencyName","freqType","freqMeasure","freqUnit","fromCode","projectName"
,"10025428",,,,,"pd",,"9 %","%",1,"MSA"
,"10025428",,,,,"psp",,"40 %","%",1,"MSA"
,"10025428",,,,,"msa",,"36 %","%",1,"MSA"
,"10212741",,,,,"depressive symptoms",,"85.7 %","%",1,"MSA"
,"10212741",,,,,"sds patients",,"28.6 %","%",1,"MSA"
,"10349344",,,,,"phenomenon",,"70 %","%",1,"MSA"
,"10349344",,,,,"snout reflex",,"80 %","%",1,"MSA"
,"10349344",,,,,"slowness verbal response",,"88 %","%",1,"MSA"
,"10534244",,,,,"nat slow acetylators",,"50 %","%",1,"MSA"
,"10577638",,,,,"per",,"84 %","%",1,"MSA"
,"10648440",,,,,"male",,"87 %","%",1,"MSA"
,"10648440",,,,,"assaulted spouses",,"64 %","%",1,"MSA"
,"10648440",,,,,"mri ct head scans",,"56 %","%",1,"MSA"
,"10648440",,,,,"neurological disorders",,"57 %","%",1,"MSA"
,"10648440",,,,,"neurological disorders",,"14 %","%",1,"MSA"
,"10648440",,,,,"parkinsons disease",,"52 %","%",1,"MSA"
,"10656512",,,,,"stimulus contrast",,"80 %","%",1,"MSA"
,"10828652",,,,,"abnormal nerve conduction",,"24 %","%",1,"MSA"
,"10828652",,,,,"msa p",,"43 %","%",1,"MSA"
,"10828652",,,,,"msa c",,"14 %","%",1,"MSA"
,"10828652",,,,,"motor nerve conduction velocities",,"4 %","%",1,"MSA"
,"10828652",,,,,"msa p patients",,"7 %","%",1,"MSA"
,"11030803",,,,,"isca patients parkinsonism",,"50 %","%",1,"MSA"
,"11244687",,,,,"idiopathic parkinsons disease",,"43.7 %","%",1,"MSA"
,"11244687",,,,,"idiopathic parkinsons disease",,"19.9 %","%",1,"MSA"
,"11244687",,,,,"idiopathic parkinsons disease",,"2.6 %","%",1,"MSA"
,"11244687",,,,,"onset parkinsons disease",,"3.3 %","%",1,"MSA"
,"11244687",,,,,"juvenile parkinsons disease",,"0.3 %","%",1,"MSA"
,"11244687",,,,,"familial parkinsons disease",,"1.7 %","%",1,"MSA"
,"11244687",,,,,"na",,"5.4 %","%",1,"MSA"
,"11244687",,,,,"vascular disease cases",,"8 %","%",1,"MSA"
,"11244687",,,,,"local lesion cases",,"3 %","%",1,"MSA"
,"11244687",,,,,"medications",,"5.3 %","%",1,"MSA"
,"11244687",,,,,"sample",,"1.5 %","%",1,"MSA"
,"11244687",,,,,"monotherapy",,"23.2 %","%",1,"MSA"
,"11244687",,,,,"two medications",,"46.7 %","%",1,"MSA"
,"11244687",,,,,"three",,"23.5 %","%",1,"MSA"
,"11244687",,,,,"levodopa",,"70.9 %","%",1,"MSA"
,"11244687",,,,,"anticholinergic",,"51.3 %","%",1,"MSA"
,"11244687",,,,,"mao b i",,"33.4 %","%",1,"MSA"
,"11244687",,,,,"amantadine",,"33.1 %","%",1,"MSA"
,"11244687",,,,,"d stimulants",,"18.5 %","%",1,"MSA"
,"11374094",,,,,"ms patients",,"84 %","%",1,"MSA"
,"11374094",,,,,"ms patients",,"56 %","%",1,"MSA"
,"11481685",,,,,"na <",,"0 %","%",1,"MSA"
,"11481685",,,,,"synucleinopathy",,"91.7 %","%",1,"MSA"
,"11481685",,,,,"synucleinopathy",,"94.3 %","%",1,"MSA"
,"11482743",,,,,"symptomatic orthostatic hypotension",,"20 %","%",1,"MSA"
,"11861684",,,,,"dystonia",,"46 %","%",1,"MSA"
,"11861684",,,,,"cervical dystonia",,"25 %","%",1,"MSA"
,"11861684",,,,,"unilateral limb dystonia",,"21 %","%",1,"MSA"
,"12013580",,,,,"encephalopathy occurred procedures",,"62 %","%",1,"MSA"
,"12013580",,,,,"slow recovery eight",,"18 %","%",1,"MSA"
,"12013580",,,,,"intermittent confusion agitation full recovery",,"6.6 %","%",1,"MSA"
,"12013580",,,,,"focal generalized seizures",,"11 %","%",1,"MSA"
,"12013580",,,,,"patients  died discharge",,"29 %","%",1,"MSA"
,"12013580",,,,,"encephalopathy",,"92 %","%",1,"MSA"
,"12023429",,,,,"patients pd",,"51 %","%",1,"MSA"
,"12023429",,,,,"sleep fragmentation",,"52.5 %","%",1,"MSA"
,"12023429",,,,,"vocalisation",,"60 %","%",1,"MSA"
,"12023429",,,,,"rem sleep behaviour disorder",,"47.5 %","%",1,"MSA"
,"12023429",,,,,"nocturnal stridor",,"19 %","%",1,"MSA"
,"12023429",,,,,"patients pd",,"30 %","%",1,"MSA"
,"12242540",,,,,"pd snd",,"5 %","%",1,"MSA"
,"12360556",,,,,"fog",,"24 %","%",1,"MSA"
,"12360556",,,,,"cbd",,"8 %","%",1,"MSA"
,"12360556",,,,,"dlb",,"21 %","%",1,"MSA"
,"12360556",,,,,"cbd",,"25 %","%",1,"MSA"
,"12360556",,,,,"msa",,"40 %","%",1,"MSA"
,"12360556",,,,,"apd fog",,"47 %","%",1,"MSA"
,"12360556",,,,,"psp",,"53 %","%",1,"MSA"
,"12360556",,,,,"msa",,"54 %","%",1,"MSA"
,"12501577",,,,,"abnormal findings",,"60 %","%",1,"MSA"
,"12501577",,,,,"depression related complaints",,"57 %","%",1,"MSA"
,"12566288",,,,,"antigliadin antibodies",,"14 %","%",1,"MSA"
,"12566288",,,,,"sporadic idiopathic group",,"41 %","%",1,"MSA"
,"12566288",,,,,"antigliadin antibodies",,"15 %","%",1,"MSA"
,"12566288",,,,,"normal controls",,"12 %","%",1,"MSA"
,"12566288",,,,,"the prevalence sporadic idiopathic group",,"32 %","%",1,"MSA"
,"12566288",,,,,"ocular signs",,"84 %","%",1,"MSA"
,"12566288",,,,,"dysarthria",,"66 %","%",1,"MSA"
,"12566288",,,,,"upper limb ataxia",,"75 %","%",1,"MSA"
,"12566288",,,,,"limb ataxia",,"90 %","%",1,"MSA"
,"12566288",,,,,"gastrointestinal symptoms",,"13 %","%",1,"MSA"
,"12566288",,,,,"atrophy cerebellum",,"79 %","%",1,"MSA"
,"12566288",,,,,"white matter hyperintensities",,"19 %","%",1,"MSA"
,"12566288",,,,,"gluten sensitive enteropathy",,"24 %","%",1,"MSA"
,"12566288",,,,,"hla dq",,"72 %","%",1,"MSA"
,"12567332",,,,,"sensitivity",,"83 %","%",1,"MSA"
,"12567332",,,,,"sensitivity",,"49 %","%",1,"MSA"
,"12567332",,,,,"between  elderly demented cases",,"20 %","%",1,"MSA"
,"12573873",,,,,"msa patients",,"75 %","%",1,"MSA"
,"12573873",,,,,"patients msa p",,"82 %","%",1,"MSA"
,"12573873",,,,,"patients msa c",,"50 %","%",1,"MSA"
,"12589575",,,,,"vermian cerebellar atrophy",,"45 %","%",1,"MSA"
,"12589575",,,,,"cortical atrophy",,"50 %","%",1,"MSA"
,"12589575",,,,,"ventricle enlargement",,"75 %","%",1,"MSA"
,"12589575",,,,,"positive predictive value ppv",,"90 %","%",1,"MSA"
,"12589575",,,,,"putaminal",,"70 %","%",1,"MSA"
,"12646759",,,,,"cases diagnosed stridor",,"69 %","%",1,"MSA"
,"12691416",,,,,"stimulation compared stimulation condition",,"15 %","%",1,"MSA"
,"12700909",,,,,"sca",,"84 %","%",1,"MSA"
,"12700909",,,,,"degenerative ataxia",,"5.2 %","%",1,"MSA"
,"12705434",,,,,"exaggerated asrs",,"86 %","%",1,"MSA"
,"12784273",,,,,"patients",,"75 %","%",1,"MSA"
,"12955551",,,,,"systemic vascular resistance",,"6 %","%",1,"MSA"
,"14502669",,,,,"misdiagnosed cases",,"70 %","%",1,"MSA"
,"14502669",,,,,"h tau haplotype",,"80 %","%",1,"MSA"
,"14502669",,,,,"hh genotype",,"66 %","%",1,"MSA"
,"14502669",,,,,"apoe epsilon carrier state",,"41 %","%",1,"MSA"
,"14506467",,,,,"patients",,"20 %","%",1,"MSA"
,"14526181",,,,,"spinocerebellar ataxias",,"40 %","%",1,"MSA"
,"14526181",,,,,"na",,"30 %","%",1,"MSA"
,"14568810",,,,,"patients excluded study",,"15 %","%",1,"MSA"
,"14568810",,,,,"patients pd",,"14 %","%",1,"MSA"
,"14568810",,,,,"patients multiple system atrophy",,"60 %","%",1,"MSA"
,"14608654",,,,,"ventricular dilatation",,"40 %","%",1,"MSA"
,"15016010",,,,,"pd",,"2.7 %","%",1,"MSA"
,"15016010",,,,,"rriv abnormalities",,"18.2 %","%",1,"MSA"
,"15016010",,,,,"rriv abnormalities",,"30 %","%",1,"MSA"
,"15253687",,,,,"nabs",,"5 %","%",1,"MSA"
,"15253687",,,,,"ifnbeta",,"24 %","%",1,"MSA"
,"15253687",,,,,"ifnbeta b",,"45 %","%",1,"MSA"
,"15258214",,,,,"patients iloca",,"85.7 %","%",1,"MSA"
,"15258214",,,,,"disturbance gait",,"90.7 %","%",1,"MSA"
,"15258214",,,,,"cerebellar syndrome",,"33.3 %","%",1,"MSA"
,"15258214",,,,,"extracerebellar neurological features",,"66.7 %","%",1,"MSA"
,"15258214",,,,,"ambulant",,"92 %","%",1,"MSA"
,"15300657",,,,,"msa patients",,"93 %","%",1,"MSA"
,"15488031",,,,,"ncis",,"9.1 %","%",1,"MSA"
,"15488031",,,,,"ncis",,"25.8 %","%",1,"MSA"
,"15488031",,,,,"nnis",,"9.2 %","%",1,"MSA"
,"15488031",,,,,"nnis",,"9.0 %","%",1,"MSA"
,"15509623",,,,,"snd",,"34 %","%",1,"MSA"
,"15509623",,,,,"opca predominant",,"17 %","%",1,"MSA"
,"15509623",,,,,"snd opca pathology",,"49 %","%",1,"MSA"
,"15509623",,,,,"lewy body pathology",,"10 %","%",1,"MSA"
,"15546601",,,,,"cgg expansions",,"4.6 %","%",1,"MSA"
,"15582091",,,,,"visual impairment",,"78 %","%",1,"MSA"
,"15582091",,,,,"genetic",,"53 %","%",1,"MSA"
,"15582091",,,,,"prenatal",,"34 %","%",1,"MSA"
,"15582091",,,,,"retinal diseases",,"31 %","%",1,"MSA"
,"15582091",,,,,"neuro ophthalmologic disorders",,"26 %","%",1,"MSA"
,"15582091",,,,,"optic nerve atrophy",,"20 %","%",1,"MSA"
,"15582091",,,,,"congenital cataract",,"13 %","%",1,"MSA"
,"15582091",,,,,"blindness",,"40 %","%",1,"MSA"
,"15582091",,,,,"blindness systemic disease multiple handicap",,"43 %","%",1,"MSA"
,"15582091",,,,,"blindness systemic disease multiple handicap",,"45 %","%",1,"MSA"
,"15824342",,,,,"hippocampal cavities",,"40 %","%",1,"MSA"
,"15824342",,,,,"hippocampal cavities",,"31 %","%",1,"MSA"
,"15824342",,,,,"cavities",,"53 %","%",1,"MSA"
,"15824342",,,,,"cavities  one normal volunteers",,"99 %","%",1,"MSA"
,"15824342",,,,,"cavities  patients tga",,"93 %","%",1,"MSA"
,"15907346",,,,,"act aa genotype  patients msa",,"20.0 %","%",1,"MSA"
,"15907346",,,,,"controls",,"10.5 %","%",1,"MSA"
,"15954131",,,,,"oh related events",,"11.5 %","%",1,"MSA"
,"15954131",,,,,"oh related events",,"12.0 %","%",1,"MSA"
,"15954131",,,,,"fludrocortisone",,"66.7 %","%",1,"MSA"
,"15954131",,,,,"heptaminol",,"42.9 %","%",1,"MSA"
,"15954131",,,,,"midodrine",,"45.5 %","%",1,"MSA"
,"15954131",,,,,"midodrine plus fludrocortisone",,"28.6 %","%",1,"MSA"
,"15956170",,,,,"middle cerebellar peduncles",,"87 %","%",1,"MSA"
,"15956170",,,,,"pons",,"97 %","%",1,"MSA"
,"15991040",,,,,"midodrine",,"49.4 %","%",1,"MSA"
,"15991040",,,,,"per patient",,"66.6 %","%",1,"MSA"
,"15991040",,,,,"serious",,"17.0 %","%",1,"MSA"
,"15991040",,,,,"unexpected",,"11.3 %","%",1,"MSA"
,"16007636",,,,,"haplotype diversity",,"95 %","%",1,"MSA"
,"16007638",,,,,"cases  investigated spemg",,"4.4 %","%",1,"MSA"
,"16007915",,,,,"g kg",,"20 %","%",1,"MSA"
,"16291887",,,,,"< year",,"25 %","%",1,"MSA"
,"16291887",,,,,"neurogenic change",,"62 % -52 %","%",1,"MSA"
,"16291887",,,,,"neurogenic change",,"83 %","%",1,"MSA"
,"16413961",,,,,"interferons beta reduce relapse rate",,"30 %","%",1,"MSA"
,"16413961",,,,,"conventional mri activity",,"50 %","%",1,"MSA"
,"16482566",,,,,"phase i",,"96 %","%",1,"MSA"
,"16482566",,,,,"phase ii",,"94 %","%",1,"MSA"
,"16482566",,,,,"parkinsonism types",,"7.2 %","%",1,"MSA"
,"16482566",,,,,"prevalence",,"3.3 %","%",1,"MSA"
,"16482566",,,,,"vascular parkinsonism",,"1.1 %","%",1,"MSA"
,"16508226",,,,,"aga",,"36 %","%",1,"MSA"
,"16508226",,,,,"disease controls without cerebellar ataxia",,"4 %","%",1,"MSA"
,"16508226",,,,,"normal controls",,"2 %","%",1,"MSA"
,"16508226",,,,,"aga positive group",,"60 %","%",1,"MSA"
,"16508226",,,,,"aga negative group",,"0 %","%",1,"MSA"
,"16543523",,,,,"haplotype diversity",,"95 %","%",1,"MSA"
,"16602104",,,,,"mean midbrain volume",,"30 %","%",1,"MSA"
,"16602104",,,,,"smaller msa p",,"15 %","%",1,"MSA"
,"16602104",,,,,"mean cerebellar volumes",,"20 %","%",1,"MSA"
,"16602104",,,,,"smaller psp",,"18 %","%",1,"MSA"
,"16602104",,,,,"smaller psp",,"25 %","%",1,"MSA"
,"16688361",,,,,"rpar",,"60 %","%",1,"MSA"
,"16688361",,,,,"females",,"40 %","%",1,"MSA"
,"16688361",,,,,"alkaline reflux gastritis",,"72.6 %","%",1,"MSA"
,"16688361",,,,,"gastroduodenal reflux",,"7.39 %","%",1,"MSA"
,"16688361",,,,,"cholecystectomy",,"5.69 %","%",1,"MSA"
,"16688361",,,,,"biliary anastomosis",,"1.73 %","%",1,"MSA"
,"16688361",,,,,"erythema gastric mucosa",,"64.43 %","%",1,"MSA"
,"16688361",,,,,"bile",,"57.83 %","%",1,"MSA"
,"16688361",,,,,"gastric folds",,"9.55 %","%",1,"MSA"
,"16688361",,,,,"erosions cases",,"5.22 %","%",1,"MSA"
,"16688361",,,,,"na",,"2.17 %","%",1,"MSA"
,"16688361",,,,,"gastric polyp one case",,"0.43 %","%",1,"MSA"
,"16688361",,,,,"chronic inflammation",,"84.06 %","%",1,"MSA"
,"16688361",,,,,"foveolar hyperplasia",,"40.44 %","%",1,"MSA"
,"16688361",,,,,"intestinal metaplasia",,"34.83 %","%",1,"MSA"
,"16688361",,,,,"helicobacter pylori infection",,"16.08 %","%",1,"MSA"
,"16688361",,,,,"gastric polyps cases",,"13.46 %","%",1,"MSA"
,"16688361",,,,,"benign ulcerations seven cases",,"11.23 %","%",1,"MSA"
,"16688361",,,,,"na edema six cases",,"3.04 %","%",1,"MSA"
,"16688361",,,,,"na",,"6.74 %","%",1,"MSA"
,"16688361",,,,,"medical study",,"2.24 %","%",1,"MSA"
,"16691119",,,,,"psp cases",,"10 %","%",1,"MSA"
,"16691119",,,,,"lbs  psp cases",,"11 %","%",1,"MSA"
,"16723388",,,,,"premutation alleles",,"1.5 %","%",1,"MSA"
,"16723388",,,,,"premutation alleles",,"2 %","%",1,"MSA"
,"16723388",,,,,"premutation alleles larger repeats",,"86 %","%",1,"MSA"
,"16723388",,,,,"premutation alleles larger repeats general population",,"22 %","%",1,"MSA"
,"16754691",,,,,"abnormal pupils",,"66 %","%",1,"MSA"
,"16754691",,,,,"pupil abnormalities bilateral symmetrical",,"85 %","%",1,"MSA"
,"16781987",,,,,"patients developed neurological disorder",,"45 %","%",1,"MSA"
,"16835130",,,,,"perfumes",,"0.5 %","%",1,"MSA"
,"16835130",,,,,"cresol",,"1.5 %","%",1,"MSA"
,"16835130",,,,,"minimal adult reproductive postnatal toxicity",,"1.0 %","%",1,"MSA"
,"16835130",,,,,"o cresol noael",,"0.2 %","%",1,"MSA"
,"16835130",,,,,"pcmc",,"2 %","%",1,"MSA"
,"16865356",,,,,"sma cases",,"95 %","%",1,"MSA"
,"17035703",,,,,"bmd",,"15.2 %","%",1,"MSA"
,"17035703",,,,,"women",,"24.6 %","%",1,"MSA"
,"17226744",,,,,"dementia",,"25 %","%",1,"MSA"
,"17226744",,,,,"clinic attendees",,"22 %","%",1,"MSA"
,"17235428",,,,,"rbd",,"0.5 %","%",1,"MSA"
,"17235428",,,,,"cases reported literature",,"60 %","%",1,"MSA"
,"17235429",,,,,"rbd",,"19 %","%",1,"MSA"
,"17235429",,,,,"rbd",,"77 %","%",1,"MSA"
,"17235429",,,,,"tauopathies",,"0 %to 27 %","%",1,"MSA"
,"17235429",,,,,"tauopathies",,"27 %","%",1,"MSA"
,"17296454",,,,,"pimecrolimus cream",,"1 %","%",1,"MSA"
,"17296454",,,,,"application site reactions",,"10.4 % -14.5 %","%",1,"MSA"
,"17296454",,,,,"nasopharyngitis",,"10.1 % -28.9 %","%",1,"MSA"
,"17296454",,,,,"headache",,"13.9 % -23.0 %","%",1,"MSA"
,"17296454",,,,,"cough",,"11.6 % -19.3 %","%",1,"MSA"
,"17296454",,,,,"pyrexia",,"7.5 % -15.4 %","%",1,"MSA"
,"17296454",,,,,"influenza",,"3.0 % -14.6 %","%",1,"MSA"
,"17324547",,,,,"multiple prca",,"6.25 %","%",1,"MSA"
,"17324547",,,,,"solitary prcc",,"12.5 %","%",1,"MSA"
,"17324547",,,,,"crccs",,"25 %","%",1,"MSA"
,"17324547",,,,,"bilateral renal tumors",,"60 %","%",1,"MSA"
,"17365256",,,,,"na",,"50 %","%",1,"MSA"
,"17514065",,,,,"co inhalation",,"5 %","%",1,"MSA"
,"17644483",,,,,"headache",,"33 %","%",1,"MSA"
,"17644483",,,,,"abnormalities gait coordination",,"27 %","%",1,"MSA"
,"17644483",,,,,"papilloedema  intracranial tumours",,"13 %","%",1,"MSA"
,"17644483",,,,,"visual acuity",,"41 %","%",1,"MSA"
,"17644483",,,,,"na",,"24 %","%",1,"MSA"
,"17644483",,,,,"children aged years intracranial tumours",,"21 %","%",1,"MSA"
,"17644483",,,,,"na",,"16 %","%",1,"MSA"
,"17644483",,,,,"intracranial tumour neurofibromatosis",,"15 %","%",1,"MSA"
,"17644483",,,,,"headache",,"75 %","%",1,"MSA"
,"17644483",,,,,"na",,"67 %","%",1,"MSA"
,"17644483",,,,,"na",,"60 %","%",1,"MSA"
,"17644483",,,,,"posterior fossa tumours",,"34 %","%",1,"MSA"
,"17644483",,,,,"na",,"47 %","%",1,"MSA"
,"17644483",,,,,"na",,"38 %","%",1,"MSA"
,"17644483",,,,,"na",,"49 %","%",1,"MSA"
,"17644483",,,,,"central brain tumours",,"19 %","%",1,"MSA"
,"17644483",,,,,"cranial nerve palsies",,"78 %","%",1,"MSA"
,"17644483",,,,,"na",,"52 %","%",1,"MSA"
,"17644483",,,,,"brainstem tumours",,"23 %","%",1,"MSA"
,"17644483",,,,,"na",,"42 %","%",1,"MSA"
,"17644483",,,,,"na",,"39 %","%",1,"MSA"
,"17644483",,,,,"spinal cord tumours",,"20 %","%",1,"MSA"
,"17712857",,,,,"sca sca mutations",,"0.5 %","%",1,"MSA"
,"18006592",,,,,"dat spect findings normal  patients",,"71 %","%",1,"MSA"
,"18006592",,,,,"abnormal mri findings suggestive atherosclerotic lesions",,"73 %","%",1,"MSA"
,"18018485",,,,,"cases showed equivalent snd opca pathologies",,"39 %","%",1,"MSA"
,"18018485",,,,,"opca showed snd predominant pathology",,"33 %","%",1,"MSA"
,"18018485",,,,,"snd predominant pathology",,"22 %","%",1,"MSA"
,"18018485",,,,,"extremely mild changes",,"6 %","%",1,"MSA"
,"18350363",,,,,"mmse abnormal",,"47 %","%",1,"MSA"
,"18350363",,,,,"patients b deficiency neurological syndromes",,"45.5 %","%",1,"MSA"
,"18368301",,,,,"prevalence oh",,"30 %","%",1,"MSA"
,"18418674",,,,,"sporadic scas",,"67.2 %","%",1,"MSA"
,"18418674",,,,,"olivopontocerebellar atrophy",,"64.7 %","%",1,"MSA"
,"18418674",,,,,"patients opca able walk least one stick",,"33 %","%",1,"MSA"
,"18418674",,,,,"patients opca able stand alone",,"43 %","%",1,"MSA"
,"18418674",,,,,"patients cca",,"76 %","%",1,"MSA"
,"18450497",,,,,"primary dystonia",,"4.18 %","%",1,"MSA"
,"18450497",,,,,"msa",,"5.26 %","%",1,"MSA"
,"18450497",,,,,"taiwanese controls",,"5 %","%",1,"MSA"
,"18553090",,,,,"incidental lewy bodies",,"15 %","%",1,"MSA"
,"18553090",,,,,"na",,"0.4 %","%",1,"MSA"
,"18553090",,,,,"gci",,"0.8 %","%",1,"MSA"
,"18553090",,,,,"per persons",,"0.004 %","%",1,"MSA"
,"18954877",,,,,"pd",,"46 %","%",1,"MSA"
,"18954877",,,,,"scd",,"42 %","%",1,"MSA"
,"18954877",,,,,"msa",,"63 %","%",1,"MSA"
,"18954877",,,,,"als",,"61 %","%",1,"MSA"
,"18971794",,,,,"doses",,"0.1 %","%",1,"MSA"
,"19099114",,,,,"dystonia",,"50 %","%",1,"MSA"
,"19099114",,,,,"=  msa group",,"30.4 %","%",1,"MSA"
,"19099114",,,,,"psp group",,"62.5 %","%",1,"MSA"
,"19101631",,,,,"corticobasal syndrome",,"31 %","%",1,"MSA"
,"19101631",,,,,"frontotemporal dementia motorneuron disease",,"29 %","%",1,"MSA"
,"19101631",,,,,"behavioral variant frontotemporal dementia",,"15 %","%",1,"MSA"
,"19101631",,,,,"primary progressive aphasia",,"9.5 %","%",1,"MSA"
,"19101631",,,,,"dementia lewy bodies",,"2 %","%",1,"MSA"
,"19101631",,,,,"progressive supranuclear palsy multiple system atrophy cases",,"0 %","%",1,"MSA"
,"19101631",,,,,"cbs",,"75 %","%",1,"MSA"
,"19101631",,,,,"ftd mnd",,"50 %","%",1,"MSA"
,"19101631",,,,,"ftd",,"27 %","%",1,"MSA"
,"19101631",,,,,"ppa",,"18 %","%",1,"MSA"
,"19101631",,,,,"familial ftld",,"28 %","%",1,"MSA"
,"19169038",,,,,"autosomal dominant cerebellar ataxias",,"40.4 %","%",1,"MSA"
,"19169038",,,,,"multiple system atrophy",,"24.7 %","%",1,"MSA"
,"19169038",,,,,"cortical cerebellar atrophy",,"13.3 %","%",1,"MSA"
,"19169038",,,,,"autosomal recessive cerebellar ataxia",,"0.3 %","%",1,"MSA"
,"19169038",,,,,"sca",,"63.3 %","%",1,"MSA"
,"19169038",,,,,"sca",,"20.0 %","%",1,"MSA"
,"19169038",,,,,"chromosome q",,"10.0 %","%",1,"MSA"
,"19169038",,,,,"dentatorubral pallidoluysian atrophy",,"4.4 %","%",1,"MSA"
,"19169038",,,,,"sca",,"1.1 %","%",1,"MSA"
,"19169038",,,,,"genetically confirmed adcas",,"90 %","%",1,"MSA"
,"19187260",,,,,"hcbs sca patients",,"8.7 %","%",1,"MSA"
,"19187260",,,,,"sca",,"25.7 %","%",1,"MSA"
,"19187260",,,,,"sca",,"1.3 %","%",1,"MSA"
,"19243063",,,,,"urinary dysfunction",,"70 %","%",1,"MSA"
,"19243063",,,,,"urinary dysfunction",,"76 %","%",1,"MSA"
,"19243063",,,,,"bowel dysfunction",,"40 %","%",1,"MSA"
,"19243063",,,,,"sexual dysfunction",,"26 %","%",1,"MSA"
,"19243063",,,,,"sexual dysfunction",,"45 %","%",1,"MSA"
,"19669613",,,,,"sleep disturbances",,"70 %","%",1,"MSA"
,"19669613",,,,,"cbd",,"36 %","%",1,"MSA"
,"19669613",,,,,"skin respiratory disorders",,"30 %","%",1,"MSA"
,"19768815",,,,,"pd",,"48 %","%",1,"MSA"
,"19768815",,,,,"psp",,"40 %","%",1,"MSA"
,"19825276",,,,,"corpus callosum",,"93 %","%",1,"MSA"
,"19825276",,,,,"cc atrophy",,"39.2 %","%",1,"MSA"
,"19825276",,,,,"patients edss",,"32 %","%",1,"MSA"
,"19825276",,,,,"patients edss",,"58 %","%",1,"MSA"
,"19825276",,,,,"edss ≥",,"24 %","%",1,"MSA"
,"19825276",,,,,"mep latency",,"43 %","%",1,"MSA"
,"19825276",,,,,"patients abnormal mep amplitude",,"85 %","%",1,"MSA"
,"19825276",,,,,"cmct",,"41 %","%",1,"MSA"
,"20012145",,,,,"patients pd + noh",,"74 %","%",1,"MSA"
,"20012145",,,,,"msa",,"68 %","%",1,"MSA"
,"20012145",,,,,"paf",,"63 %","%",1,"MSA"
,"20012145",,,,,"pd without noh",,"28 %","%",1,"MSA"
,"20012145",,,,,"pd",,"24 %","%",1,"MSA"
,"20108376",,,,,"pd years age",,"3.4 %","%",1,"MSA"
,"20108376",,,,,"women",,"2.6 %","%",1,"MSA"
,"20108376",,,,,"the cumulative incidence pd",,"2.9 %","%",1,"MSA"
,"20108378",,,,,"new cases pd",,"34 %","%",1,"MSA"
,"20108378",,,,,"aps  comorbid depressive symptoms",,"50 %","%",1,"MSA"
,"20142524",,,,,"ftd spectrum cases",,"6.9 %","%",1,"MSA"
,"20142524",,,,,"cases pathological diagnosis ftld u",,"21.4 %","%",1,"MSA"
,"20142524",,,,,"ftd spectrum cases",,"16.0 %","%",1,"MSA"
,"20142524",,,,,"cases ftld u family history",,"56.2 %","%",1,"MSA"
,"20157015",,,,,"mutational carriers",,"20 %","%",1,"MSA"
,"20195938",,,,,"parkinsonian patients abnormal echogenity substantia nigra",,"90 %","%",1,"MSA"
,"20195938",,,,,"normal population",,"10 %","%",1,"MSA"
,"20385007",,,,,"limit normal",,"10 %","%",1,"MSA"
,"20479358",,,,,"dlb",,"12 %","%",1,"MSA"
,"20479358",,,,,"pd",,"7 %","%",1,"MSA"
,"20571046",,,,,"cases opc predominant pathology",,"40 %","%",1,"MSA"
,"20571046",,,,,"strn predominant pathology",,"18 %","%",1,"MSA"
,"20571046",,,,,"strn opc pathology",,"42 %","%",1,"MSA"
,"20571046",,,,,"opc predominant pathology",,"17 %","%",1,"MSA"
,"20571046",,,,,"strn predominant pathology",,"34 %","%",1,"MSA"
,"20571046",,,,,"equivalent strn opc pathology",,"49 %","%",1,"MSA"
,"20658542",,,,,"urinary urgency",,"76 %","%",1,"MSA"
,"20658542",,,,,"constipation",,"58 %","%",1,"MSA"
,"20658542",,,,,"urination",,"79 %","%",1,"MSA"
,"20658542",,,,,"na",,"72 %","%",1,"MSA"
,"20658542",,,,,"na",,"31 %","%",1,"MSA"
,"20669316",,,,,"persons idiopathic rem sleep behavior disorder",,"50 %","%",1,"MSA"
,"20669316",,,,,"male",,"86 %","%",1,"MSA"
,"21088341",,,,,"spinocerebellar ataxia",,"77.7 %","%",1,"MSA"
,"21088341",,,,,"cases",,"10.6 %","%",1,"MSA"
,"21305587",,,,,"brain diseases",,"9.6 %","%",1,"MSA"
,"21305587",,,,,"psychogenic bladder dysfunction",,"20.0 %","%",1,"MSA"
,"21305587",,,,,"parkinsons disease",,"8.1 %","%",1,"MSA"
,"21320989",,,,,"patients msa",,"28 %","%",1,"MSA"
,"21320989",,,,,"patients pd",,"29 %","%",1,"MSA"
,"21320989",,,,,"healthy subjects",,"2 %","%",1,"MSA"
,"21320989",,,,,"patients pd",,"14 %","%",1,"MSA"
,"21320989",,,,,"healthy subjects",,"7 %","%",1,"MSA"
,"2138923",,,,,"most lesions  patients primary progressive disease",,"85 %","%",1,"MSA"
,"21553114",,,,,"urinary symptoms",,"60 %","%",1,"MSA"
,"21660918",,,,,"female",,"74.1 %","%",1,"MSA"
,"21660918",,,,,"oh",,"29.3 %","%",1,"MSA"
,"21689962",,,,,"symptomatic oh",,"81 %","%",1,"MSA"
,"21689962",,,,,"pd patients",,"18 %","%",1,"MSA"
,"21689962",,,,,"patients non msa atypical parkinsonism",,"19 %","%",1,"MSA"
,"21738024",,,,,"two  subjects condition diagnosed icd",,"10 %","%",1,"MSA"
,"21813140",,,,,"dlb",,"18 %","%",1,"MSA"
,"21813140",,,,,"pd",,"7.5 %","%",1,"MSA"
,"21813140",,,,,"sfmd psychiatric patients",,"2 %","%",1,"MSA"
,"21813140",,,,,"catatonic signs",,"55 %","%",1,"MSA"
,"21813140",,,,,"dlb pd patients",,"92 %","%",1,"MSA"
,"21813140",,,,,"sfmd recurrent follow",,"70 %","%",1,"MSA"
,"21813140",,,,,"dlb pd patients",,"93 %","%",1,"MSA"
,"22077446",,,,,"patients enrolled recent parkinson disease pd trials",,"15 %","%",1,"MSA"
,"22226624",,,,,"calorie intake diet",,"30 %","%",1,"MSA"
,"22226624",,,,,"total loss csa  cr animals",,"15 %","%",1,"MSA"
,"22226624",,,,,"controls",,"36 %","%",1,"MSA"
,"22445241",,,,,"hospitalizations",,"0.4 %","%",1,"MSA"
,"22445241",,,,,"unselected elders",,"30 %","%",1,"MSA"
,"22481508",,,,,"pd patients",,"90 %","%",1,"MSA"
,"22588254",,,,,"male predominance",,"60.2 %","%",1,"MSA"
,"22588254",,,,,"central nervous system",,"61.4 %","%",1,"MSA"
,"22588254",,,,,"cerebral ischaemia",,"27.7 %","%",1,"MSA"
,"22629254",,,,,"rbd occurs approximately  general population",,"0.5 %","%",1,"MSA"
,"22629254",,,,,"mild cognitive impairment",,"50 %","%",1,"MSA"
,"22708511",,,,,"normal subjects",,"38.5 %","%",1,"MSA"
,"22908195",,,,,"people years age",,"10 %","%",1,"MSA"
,"23049679",,,,,"persistent orthostatic blood pressure",,"50 %","%",1,"MSA"
,"23049679",,,,,"constipation",,"30 %","%",1,"MSA"
,"23075668",,,,,"atypical parkinsonism",,"7.41 %","%",1,"MSA"
,"23075668",,,,,"ipd",,"3.26 %","%",1,"MSA"
,"23108490",,,,,"ataxia cases",,"0.1 %","%",1,"MSA"
,"23116490",,,,,"healthy subjects",,"28 %","%",1,"MSA"
,"23116490",,,,,"na",,"2 %","%",1,"MSA"
,"23116490",,,,,"eds",,"24 %","%",1,"MSA"
,"23116490",,,,,"sdb abnormal plms",,"96 %","%",1,"MSA"
,"23116490",,,,,"eds",,"25 %","%",1,"MSA"
,"23116490",,,,,"eds",,"18 %","%",1,"MSA"
,"23192520",,,,,"survival rates",,"74 %","%",1,"MSA"
,"23192520",,,,,"survival rates",,"28 %","%",1,"MSA"
,"23208011",,,,,"pain fatigue day time somnolence problems mobility",,"80 %","%",1,"MSA"
,"23208011",,,,,"constipation",,"50 % -80 %","%",1,"MSA"
,"23208011",,,,,"anxiety",,"70 %","%",1,"MSA"
,"23208011",,,,,"depressed",,"60 %","%",1,"MSA"
,"23208011",,,,,"practical problems still needed addressed",,"42 %","%",1,"MSA"
,"23289171",,,,,"symptomatic bradycardia",,"0.5 %","%",1,"MSA"
,"23289171",,,,,"mobitz i type ii atrioventricular blocks",,"0.2 %","%",1,"MSA"
,"23289171",,,,,"incidence mobitz i type ii atrioventricular blocks",,"0.1 %","%",1,"MSA"
,"23333538",,,,,"sleep",,"2.9 %","%",1,"MSA"
,"23333538",,,,,"pd",,"11.9 %","%",1,"MSA"
,"23480488",,,,,"altered hva",,"20 %","%",1,"MSA"
,"23562390",,,,,"developed defined neurodegenerative syndrome",,"82 %","%",1,"MSA"
,"23562390",,,,,"neurological disease free survival",,"65.2 %","%",1,"MSA"
,"23916653",,,,,"om  disorder",,"17.2 %","%",1,"MSA"
,"23916653",,,,,"orthostatic tremor",,"13.9 %","%",1,"MSA"
,"23916653",,,,,"orthostatism",,"12.9 %","%",1,"MSA"
,"23916653",,,,,"neurodegenerative disease",,"68.7 %","%",1,"MSA"
,"24023619",,,,,"data",,"20 %","%",1,"MSA"
,"24116345",,,,,"msa patients show tremor",,"80 %","%",1,"MSA"
,"24116345",,,,,"rest tremor",,"10 %","%",1,"MSA"
,"24169076",,,,,"re als plus individuals",,"22.2 %","%",1,"MSA"
,"24267739",,,,,"sensitivity ep",,"43.5 %","%",1,"MSA"
,"24267739",,,,,"msa",,"76.9 %","%",1,"MSA"
,"24267739",,,,,"sensitivity",,"65.2 %","%",1,"MSA"
,"24267739",,,,,"msa",,"92.3 %","%",1,"MSA"
,"24299027",,,,,"exhibited abnormalities neurological examination",,"53 %","%",1,"MSA"
,"24299027",,,,,"patients displayed abnormalities mri",,"37 %","%",1,"MSA"
,"24337696",,,,,"possible",,"12 %","%",1,"MSA"
,"24337696",,,,,"probable msa",,"88 %","%",1,"MSA"
,"24337696",,,,,"msa c",,"40 %","%",1,"MSA"
,"24337696",,,,,"male prevalence",,"60 %","%",1,"MSA"
,"24337696",,,,,"oh",,"69 %","%",1,"MSA"
,"24399499",,,,,"neurodegenerative disorder α synucleinopathy type",,"80 %","%",1,"MSA"
,"24487796",,,,,"women",,"52 %","%",1,"MSA"
,"24487796",,,,,"clinicopathological diagnoses",,"25 %","%",1,"MSA"
,"24487796",,,,,"alzheimer disease",,"17 %","%",1,"MSA"
,"24487796",,,,,"vascular dementia",,"6 %","%",1,"MSA"
,"24487796",,,,,"progressive supranuclear palsy",,"3 %","%",1,"MSA"
,"24487796",,,,,"multiple system atrophy",,"0.8 %","%",1,"MSA"
,"24487796",,,,,"clinically normal death",,"73 %","%",1,"MSA"
,"24487796",,,,,"ad pathology",,"38 %","%",1,"MSA"
,"24487796",,,,,"incidental lewy bodies",,"20 %","%",1,"MSA"
,"24487796",,,,,"progressive supranuclear palsy",,"5 %","%",1,"MSA"
,"24501436",,,,,"neuronal depletion",,"56 %","%",1,"MSA"
,"24501436",,,,,"loss prebötc dlb",,"40 %","%",1,"MSA"
,"24501436",,,,,"loss msa",,"68 %","%",1,"MSA"
,"24501436",,,,,"loss rpa dlb",,"46 %","%",1,"MSA"
,"24501436",,,,,"loss msa p <",,"73 %","%",1,"MSA"
,"24602369",,,,,"neutral buffered formalin",,"10 %","%",1,"MSA"
,"24606999",,,,,"patients definite sus",,"25 %","%",1,"MSA"
,"24606999",,,,,"controls",,"4.3 %","%",1,"MSA"
,"24606999",,,,,"igm aeca",,"45 %","%",1,"MSA"
,"24613864",,,,,"rbd",,"72 %","%",1,"MSA"
,"24743700",,,,,"pure",,"98 %","%",1,"MSA"
,"24814713",,,,,"men",,"61 %","%",1,"MSA"
,"24818598",,,,,"periodic limb movements",,"75 %","%",1,"MSA"
,"24868396",,,,,"hemi bilateral putaminal hypointensity",,"81.8 %","%",1,"MSA"
,"24868396",,,,,"msa",,"54.5 %","%",1,"MSA"
,"25000926",,,,,"discontinued cpap treatment",,"66 %","%",1,"MSA"
,"25000926",,,,,"p =",,"15 %","%",1,"MSA"
,"25158223",,,,,"acne scars",,"42.3 %","%",1,"MSA"
,"25208467",,,,,"oligodendroglial cells",,"62.4 %","%",1,"MSA"
,"25208467",,,,,"nuclear tppp",,"48.6 %","%",1,"MSA"
,"25208467",,,,,"nuclear tppp",,"19.6 %","%",1,"MSA"
,"25253555",,,,,"ms",,"32 %","%",1,"MSA"
,"25253555",,,,,"patients dementia",,"57 %","%",1,"MSA"
,"25253555",,,,,"patients msa",,"73 %","%",1,"MSA"
,"25298309",,,,,"mutations sca genes",,"7.3 %","%",1,"MSA"
,"25298309",,,,,"rem sleep behavior disorder",,"81.8 %","%",1,"MSA"
,"25355454",,,,,"severe intellectual disability",,"84 %","%",1,"MSA"
,"25355454",,,,,"microcephaly",,"81 %","%",1,"MSA"
,"25355454",,,,,"independent ambulation",,"82 %","%",1,"MSA"
,"25355454",,,,,"borderline mild intellectual disability",,"64 %","%",1,"MSA"
,"25355454",,,,,"microcephaly",,"35 %","%",1,"MSA"
,"25355454",,,,,"patients mild phenotype",,"70 %","%",1,"MSA"
,"25442117",,,,,"msa patients",,"4.17 %","%",1,"MSA"
,"25442117",,,,,"coq",,"3.01 %","%",1,"MSA"
,"25442117",,,,,"coq",,"1.28 %","%",1,"MSA"
,"25459246",,,,,"pd patients",,"58 %","%",1,"MSA"
,"25459246",,,,,"msa",,"81.9 %","%",1,"MSA"
,"25459246",,,,,"dlb",,"74 %","%",1,"MSA"
,"25459246",,,,,"psp",,"36.7 %","%",1,"MSA"
,"25459246",,,,,"cbd",,"5.5 %","%",1,"MSA"
,"25459246",,,,,"positive predictive value ppv prbd",,"82.3 %","%",1,"MSA"
,"25459246",,,,,"sensitivity",,"69.4 %","%",1,"MSA"
,"25459246",,,,,"specificity",,"68.6 %","%",1,"MSA"
,"25534084",,,,,"pd",,"64.3 %","%",1,"MSA"
,"25534084",,,,,"msa",,"31.5 %","%",1,"MSA"
,"25641760",,,,,"carriers least one disease",,"33.2 %","%",1,"MSA"
,"25641760",,,,,"carriers two diseases",,"7.7 %","%",1,"MSA"
,"25641760",,,,,"carrier frequencies",,"14.3 %","%",1,"MSA"
,"25641760",,,,,"carrier frequencies",,"11.2 %","%",1,"MSA"
,"25641760",,,,,"carrier frequencies",,"6.1 %","%",1,"MSA"
,"25641760",,,,,"positive family history one diseases",,"57.8 %","%",1,"MSA"
,"25641760",,,,,"negative family history",,"25.8 %","%",1,"MSA"
,"25739474",,,,,"clinically suspected rbd",,"76.1 %","%",1,"MSA"
,"25739474",,,,,"polysomnography confirmed rbd",,"81 %","%",1,"MSA"
,"25739474",,,,,"clinically suspected rbd",,"73 %","%",1,"MSA"
,"25739474",,,,,"polysomnography confirmed rbd",,"88 %","%",1,"MSA"
,"25875517",,,,,"sigmoid torsion",,"74.7 %","%",1,"MSA"
,"25875517",,,,,"radiological diagnosis",,"84 %","%",1,"MSA"
,"25875517",,,,,"endoscopic decompression",,"88.7 %","%",1,"MSA"
,"25875517",,,,,"patients serology positive chagas disease",,"22 %","%",1,"MSA"
,"25875517",,,,,"serology negative",,"21.44 %","%",1,"MSA"
,"25895507",,,,,"oculomotor dysfunction frequency",,"38 %","%",1,"MSA"
,"25895507",,,,,"oculomotor dysfunction frequency",,"33 %","%",1,"MSA"
,"25895507",,,,,"patients posterior cortical atrophy",,"80 %","%",1,"MSA"
,"25895507",,,,,"typical alzheimers disease",,"17 %","%",1,"MSA"
,"25895507",,,,,"controls",,"5 %","%",1,"MSA"
,"25977831",,,,,"dementia",,"2.7 %","%",1,"MSA"
,"25977831",,,,,"et",,"1.1 %","%",1,"MSA"
,"25977831",,,,,"controls",,"2.5 %","%",1,"MSA"
,"26054882",,,,,"orthostatic hypotension",,"47.6 %","%",1,"MSA"
,"26054882",,,,,"controls  patients  controls",,"0 %","%",1,"MSA"
,"26054882",,,,,"reduction total peripheral resistance",,"69.5 %","%",1,"MSA"
,"26098829",,,,,"patients pd",,"4.08 %","%",1,"MSA"
,"26098829",,,,,"controls",,"1.86 %","%",1,"MSA"
,"26194201",,,,,"bladder dysfunction",,"47 %","%",1,"MSA"
,"26194201",,,,,"gait problems",,"33 %","%",1,"MSA"
,"26194201",,,,,"spasticity legs",,"93 %","%",1,"MSA"
,"26194201",,,,,"distal sensory deficit",,"80 %","%",1,"MSA"
,"26194201",,,,,"leukoencephalopathy",,"97 %","%",1,"MSA"
,"26194201",,,,,"cerebral small vessel disease",,"27 %","%",1,"MSA"
,"26194201",,,,,"multiple sclerosis",,"17 %","%",1,"MSA"
,"26194201",,,,,"peripheral neuropathies",,"20 %","%",1,"MSA"
,"26194201",,,,,"urinary tract symptoms",,"60 %","%",1,"MSA"
,"26205436",,,,,"food stagnation",,"25 %","%",1,"MSA"
,"26253930",,,,,"laterality",,"64 %","%",1,"MSA"
,"26253930",,,,,"atrophy",,"61 %","%",1,"MSA"
,"26253930",,,,,"atrophy",,"21 %","%",1,"MSA"
,"26253930",,,,,"atrophy",,"71 %","%",1,"MSA"
,"26253930",,,,,"laterality cerebellar mcp atrophy",,"57 %","%",1,"MSA"
,"26253930",,,,,"patients",,"11 %","%",1,"MSA"
,"26253930",,,,,"patients",,"25 %","%",1,"MSA"
,"26253930",,,,,"matched laterality",,"33 %","%",1,"MSA"
,"26253930",,,,,"mismatched laterality",,"27 %","%",1,"MSA"
,"26253930",,,,,"laterality",,"13 %","%",1,"MSA"
,"26253930",,,,,"patients",,"75 %","%",1,"MSA"
,"26359854",,,,,"cognitive dysfunction",,"38 %","%",1,"MSA"
,"26467153",,,,,"iloca ± years",,"33 %","%",1,"MSA"
,"26566913",,,,,"δtapmax",,"20 %","%",1,"MSA"
,"26590992",,,,,"patients",,"7.3 %","%",1,"MSA"
,"26590992",,,,,"patients",,"1.86 %","%",1,"MSA"
,"26686342",,,,,"stomach",,"31.6 %","%",1,"MSA"
,"26686342",,,,,"colon",,"10.4 %","%",1,"MSA"
,"26686342",,,,,"stomach",,"40.0 %","%",1,"MSA"
,"26686342",,,,,"colon",,"8.0 %","%",1,"MSA"
,"26686342",,,,,"stomach",,"33.3 %","%",1,"MSA"
,"26686342",,,,,"colon",,"18.5 %","%",1,"MSA"
,"26756744",,,,,"pd subjects",,"89 %","%",1,"MSA"
,"26756744",,,,,"dlb",,"71 %","%",1,"MSA"
,"26756744",,,,,"ilbd subjects none control subjects",,"11 %","%",1,"MSA"
,"26801189",,,,,"pd patients",,"34 %","%",1,"MSA"
,"26801189",,,,,"mild",,"71 %","%",1,"MSA"
,"26801189",,,,,"moderate",,"27 %","%",1,"MSA"
,"26801189",,,,,"severe",,"2 %","%",1,"MSA"
,"26801189",,,,,"msa ones",,"37 %","%",1,"MSA"
,"26801189",,,,,"mild",,"55 %","%",1,"MSA"
,"26801189",,,,,"severe",,"17 %","%",1,"MSA"
,"26801189",,,,,"na  greater systolic",,"28 %","%",1,"MSA"
,"26841329",,,,,"mayo clinic patient series",,"1 %","%",1,"MSA"
,"26886104",,,,,"symptoms",,"57 %","%",1,"MSA"
,"26886104",,,,,"patients psp",,"56 %","%",1,"MSA"
,"26886104",,,,,"patients psp",,"81 %","%",1,"MSA"
,"26886104",,,,,"pd",,"69 %","%",1,"MSA"
,"26886104",,,,,"msa",,"67 %","%",1,"MSA"
,"26900156",,,,,"cases per persons",,"0.4 %","%",1,"MSA"
,"27364040",,,,,"psp patients",,"35.7 %","%",1,"MSA"
,"27364040",,,,,"msa patients",,"13.3 %","%",1,"MSA"
,"27364040",,,,,"et patient",,"12.5 %","%",1,"MSA"
,"27364040",,,,,"controls",,"10 %","%",1,"MSA"
,"27623111",,,,,"pd",,"81 %","%",1,"MSA"
,"27623111",,,,,"parkinson plus syndromes",,"19 %","%",1,"MSA"
,"27623111",,,,,"pain",,"74 %","%",1,"MSA"
,"27623111",,,,,"parkinson plus syndromes",,"50 %","%",1,"MSA"
,"27623111",,,,,"tauopathies",,"40 %","%",1,"MSA"
,"27623111",,,,,"central pain",,"32 %","%",1,"MSA"
,"27623111",,,,,"central pain",,"4 %","%",1,"MSA"
,"27623111",,,,,"pd",,"21 %","%",1,"MSA"
,"27623111",,,,,"only patients  experienced pain treated pain medications",,"48 %","%",1,"MSA"
,"27636856",,,,,"initial improvements baseline patient reported noh symptom severity",,"50 %","%",1,"MSA"
,"27636856",,,,,"cardiac aes",,"2 %","%",1,"MSA"
,"27760012",,,,,"patients",,"75 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"63 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"59 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"95 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"90 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"57 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"48 %","%",1,"MSA"
,"27859565",,,,,"anhidrosis",,"38 %","%",1,"MSA"
,"27859565",,,,,"global",,"35 %","%",1,"MSA"
,"27859565",,,,,"the site lesion preganglionic",,"47 %","%",1,"MSA"
,"27859565",,,,,"repeat thermoregulatory sweat tests",,"6.2 %","%",1,"MSA"
,"27890451",,,,,"cut values",,"95 %","%",1,"MSA"
,"27890451",,,,,"sensitivity specificity",,"87.0 %","%",1,"MSA"
,"27890451",,,,,"sensitivity",,"76.7 %","%",1,"MSA"
,"27890451",,,,,"specificity",,"95.7 %","%",1,"MSA"
,"28159196",,,,,"rates cardiovascular adverse events",,"4.4 %","%",1,"MSA"
,"28159196",,,,,"long term open label studies",,"10.8 %","%",1,"MSA"
,"28159196",,,,,"the incidence treatment discontinuation",,"2.5 %","%",1,"MSA"
,"28207803",,,,,"pd patients",,"23.5 %","%",1,"MSA"
,"28207803",,,,,"msa",,"90 %","%",1,"MSA"
,"28207803",,,,,"psp",,"41.7 %","%",1,"MSA"
,"28207803",,,,,"cbd",,"57 %","%",1,"MSA"
,"28601572",,,,,"cognitive decline",,"80 %","%",1,"MSA"
,"28748633",,,,,"patients least mild depression anxiety symptoms",,"62.0 %","%",1,"MSA"
,"28748633",,,,,"mild depression anxiety symptoms",,"71.7 %","%",1,"MSA"
,"28782341",,,,,"non msa c sporadic cerebellar ataxia cases",,"57 %","%",1,"MSA"
,"28782341",,,,,"abnormalities sca",,"36 %","%",1,"MSA"
,"28782341",,,,,"sca",,"7.1 %","%",1,"MSA"
,"28782341",,,,,"drpla",,"3.6 %","%",1,"MSA"
,"28782341",,,,,"familial cerebellar ataxia cases",,"75 %","%",1,"MSA"
,"28782341",,,,,"abnormalities sca",,"29 %","%",1,"MSA"
,"28843020",,,,,"neurodegenerative disease diagnosis",,"9 %","%",1,"MSA"
,"28843020",,,,,"clinical pathological concordance",,"86.7 %","%",1,"MSA"
,"28843020",,,,,"clinical pathological discrepancy",,"13.3 %","%",1,"MSA"
,"28966932",,,,,"gba variants",,"3.7 %","%",1,"MSA"
,"29027029",,,,,"msa c patients",,"97.5 %","%",1,"MSA"
,"29027029",,,,,"msa p patients",,"24.1 %","%",1,"MSA"
,"29406901",,,,,"degenerative parkinsonism",,"2.1 %","%",1,"MSA"
,"29406901",,,,,"patients degenerative conditions",,"1.3 %","%",1,"MSA"
,"29458746",,,,,"disorders",,"62.2 %","%",1,"MSA"
,"29458746",,,,,"disorders",,"38 %","%",1,"MSA"
,"29458746",,,,,"obstructive sleep apnea",,"31 %","%",1,"MSA"
,"29458746",,,,,"central sleep apnea",,"9 %","%",1,"MSA"
,"29661694",,,,,"degenerative form",,"80 %","%",1,"MSA"
,"29661694",,,,,"non degenerative form parkinsonism",,"20 %","%",1,"MSA"
,"29661694",,,,,"parkinsonism",,"81 %","%",1,"MSA"
,"29661694",,,,,"dementia lewy bodies",,"9 %","%",1,"MSA"
,"29661694",,,,,"progressive supranuclear palsy",,"3.9 %","%",1,"MSA"
,"29661694",,,,,"na",,"1.9 %","%",1,"MSA"
,"29661694",,,,,"drug induced parkinsonism",,"43.4 %","%",1,"MSA"
,"29661694",,,,,"vascular parkinsonism",,"37 %","%",1,"MSA"
,"29661694",,,,,"normal pressure hydrocephalus",,"5.1 %","%",1,"MSA"
,"29661694",,,,,"parkinsonism context psychiatric disorder functional parkinsonism",,"3.8 %","%",1,"MSA"
,"29783976",,,,,"schizophrenia",,"1 %","%",1,"MSA"
,"29785965",,,,,"pd",,"22 %","%",1,"MSA"
,"29878075",,,,,"α synuclein",,"22 %","%",1,"MSA"
,"29878075",,,,,"corticobasal disease",,"24 %","%",1,"MSA"
,"29878075",,,,,"amyloid β",,"80 %","%",1,"MSA"
,"29971977",,,,,"familial patients",,"16.6 %","%",1,"MSA"
,"29971977",,,,,"non familial cases",,"83.4 %","%",1,"MSA"
,"29971977",,,,,"genetic diagnoses",,"72 %","%",1,"MSA"
,"29971977",,,,,"nonfamilial patients",,"11 %","%",1,"MSA"
,"29971977",,,,,"progressive ataxias",,"20.7 %","%",1,"MSA"
,"29971977",,,,,"sporadic",,"62.9 %","%",1,"MSA"
,"29971977",,,,,"secondary",,"5.2 %","%",1,"MSA"
,"29971977",,,,,"undetermined ataxia",,"11.1 %","%",1,"MSA"
,"29971977",,,,,"multiple system atrophy",,"57.3 %","%",1,"MSA"
,"29971977",,,,,"spinocerebellar ataxia",,"89.4 %","%",1,"MSA"
,"29991992",,,,,"cancers",,"50 %","%",1,"MSA"
,"30062008",,,,,"msa p patients",,"38.4 %","%",1,"MSA"
,"30062008",,,,,"specificity",,"61.6 %","%",1,"MSA"
,"30062008",,,,,"sn hyperechogenicity",,"46.3 %","%",1,"MSA"
,"30062008",,,,,"sn hyperechogenicity",,"69.8 %","%",1,"MSA"
,"30062008",,,,,"sn hyperechogenicity",,"52.2 %","%",1,"MSA"
,"30062008",,,,,"sn hyperechogenicity",,"66.7 %","%",1,"MSA"
,"30103064",,,,,"pd",,"12.7 %","%",1,"MSA"
,"30103064",,,,,"pd",,"11.1 %","%",1,"MSA"
,"30103064",,,,,"pd patients",,"0 %","%",1,"MSA"
,"30103064",,,,,"pd",,"1.6 %","%",1,"MSA"
,"30103064",,,,,"msa",,"5.9 %","%",1,"MSA"
,"30103064",,,,,"msa patients",,"11.8 %","%",1,"MSA"
,"30103064",,,,,"pd patients",,"9.1 %","%",1,"MSA"
,"30103064",,,,,"pd patients",,"25.4 %","%",1,"MSA"
,"30144800",,,,,"patients",,"90 %","%",1,"MSA"
,"30144800",,,,,"individuals managed caregivers",,"88 %","%",1,"MSA"
,"30144800",,,,,"patients",,"36 %","%",1,"MSA"
,"30144800",,,,,"caregivers",,"16 %","%",1,"MSA"
,"30144800",,,,,"patients",,"59 %","%",1,"MSA"
,"30144800",,,,,"caregivers",,"75 %","%",1,"MSA"
,"30144800",,,,,"noh symptoms adversely affected patients ability perform everyday activities",,"87 %","%",1,"MSA"
,"30144800",,,,,"patients",,"57 %","%",1,"MSA"
,"30144800",,,,,"caregivers",,"80 %","%",1,"MSA"
,"30203094",,,,,"snd cases",,"6.94 %","%",1,"MSA"
,"30203094",,,,,"normal",,"0 %","%",1,"MSA"
,"30203094",,,,,"neurodegenerative disease pathologies",,"0.74 %","%",1,"MSA"
,"30345277",,,,,"male predominance",,"68 %","%",1,"MSA"
,"30345277",,,,,"patients",,"56 %","%",1,"MSA"
,"30345277",,,,,"patients",,"32 %","%",1,"MSA"
,"30345277",,,,,"patients",,"12 %","%",1,"MSA"
,"30345277",,,,,"patients",,"44 %","%",1,"MSA"
,"30485545",,,,,"indian population",,"0.0008 %to 0.0","%",1,"MSA"
,"30485545",,,,,"indian population",,"0.002 %","%",1,"MSA"
,"30619056",,,,,"cases als",,"1.6 %","%",1,"MSA"
,"30619056",,,,,"female",,"55 %","%",1,"MSA"
,"30619056",,,,,"bulbar onset",,"35 %","%",1,"MSA"
,"30619056",,,,,"limb onset",,"45 %","%",1,"MSA"
,"30619056",,,,,"underwent artificial ventilations",,"50 %","%",1,"MSA"
,"30619056",,,,,"factors",,"17 %","%",1,"MSA"
,"30805069",,,,,"pain",,"42.85 %","%",1,"MSA"
,"30805069",,,,,"pain received treatment",,"43.33 %","%",1,"MSA"
,"30818962",,,,,"dry air",,"94 %","%",1,"MSA"
,"30818962",,,,,"changes season weather",,"60 %","%",1,"MSA"
,"30818962",,,,,"indoors outdoors",,"40 %","%",1,"MSA"
,"31088653",,,,,"recent increases american people aged",,"49 %","%",1,"MSA"
,"31105016",,,,,"low prevalence",,"0.2 %","%",1,"MSA"
,"31371567",,,,,"compliance",,"10.7 %","%",1,"MSA"
,"31371567",,,,,"postvoid residual",,"74.8 %","%",1,"MSA"
,"31371567",,,,,"postvoid residual",,"75.9 %","%",1,"MSA"
,"31371567",,,,,"uroflow",,"72.6 %","%",1,"MSA"
,"31371567",,,,,"detrusor pressure maximal uroflow",,"70.5 %","%",1,"MSA"
,"31371567",,,,,"uroflowmetry",,"71.0 %","%",1,"MSA"
,"31692664",,,,,"idiopathic parkinsons disease",,"64.42 %","%",1,"MSA"
,"31692664",,,,,"parkinsonian syndrome",,"35.47 %","%",1,"MSA"
,"31692664",,,,,"tremor dominant parkinsons disease",,"35.42 %","%",1,"MSA"
,"31692664",,,,,"cases",,"41.71 %","%",1,"MSA"
,"31692664",,,,,"parkinsons disease",,"22.38 %","%",1,"MSA"
,"31692664",,,,,"parkinsonian syndromes",,"72.97 %","%",1,"MSA"
,"31692664",,,,,"multiple system atrophy",,"46.64 %","%",1,"MSA"
,"31832904",,,,,"males diagnosed rbd",,"33 %","%",1,"MSA"
,"31860007",,,,,"male",,"58.1 %","%",1,"MSA"
,"31860007",,,,,"postmortem evaluation",,"92.3 %","%",1,"MSA"
,"31860007",,,,,"psp",,"48.5 %","%",1,"MSA"
,"31860007",,,,,"cbs",,"47.1 %","%",1,"MSA"
,"31861253",,,,,"ln hyperechogenicity aps",,"76 %","%",1,"MSA"
,"31861253",,,,,"pd",,"16 %","%",1,"MSA"
,"31957322",,,,,"escc",,"4.0 %","%",1,"MSA"
,"31957322",,,,,"ga",,"1.4 %","%",1,"MSA"
,"31957322",,,,,"hnscc detection rate",,"1.1 %","%",1,"MSA"
,"31992680",,,,,"tbi frequency",,"7.0 %","%",1,"MSA"
,"31992680",,,,,"tbi frequency",,"8.2 %","%",1,"MSA"
,"32032926",,,,,"cvemps",,"46.7 %","%",1,"MSA"
,"32032926",,,,,"subjects",,"13.3 %","%",1,"MSA"
,"32032926",,,,,"msa patients",,"26.7 %","%",1,"MSA"
,"32032926",,,,,"subjects",,"40 %","%",1,"MSA"
,"32088203",,,,,"female",,"65 %","%",1,"MSA"
,"32088203",,,,,"female",,"67 %","%",1,"MSA"
,"32146096",,,,,"abnormal tremor",,"65 %","%",1,"MSA"
,"32146096",,,,,"essential tremor",,"50 %","%",1,"MSA"
,"32146096",,,,,"cerebellar ataxia",,"40 %","%",1,"MSA"
,"32146096",,,,,"progressive supranuclear palsy",,"25 %","%",1,"MSA"
,"32146096",,,,,"parkinsons disease",,"20 %","%",1,"MSA"
,"32146096",,,,,"na",,"10 %","%",1,"MSA"
,"32146096",,,,,"na  controls",,"8 %","%",1,"MSA"
,"32232888",,,,,"lbd observed msa patients",,"5 %","%",1,"MSA"
,"32234335",,,,,"oh",,"53.1 %","%",1,"MSA"
,"32234335",,,,,"bp < mmhg",,"67 %","%",1,"MSA"
,"32234335",,,,,"bp",,"91 %","%",1,"MSA"
,"32234825",,,,,"pre rbd",,"27 %","%",1,"MSA"
,"32340608",,,,,"msa c",,"91.7 %","%",1,"MSA"
,"32340608",,,,,"msa c",,"60.0 %","%",1,"MSA"
,"32340608",,,,,"msa c",,"66.7 %","%",1,"MSA"
,"32348986",,,,,"dysarthria",,"98.4 %","%",1,"MSA"
,"32348986",,,,,"sexual dysfunction",,"95.1 %","%",1,"MSA"
,"32348986",,,,,"probable rem sleep behavior disorder",,"90.2 %","%",1,"MSA"
,"32348986",,,,,"constipation",,"82.0 %","%",1,"MSA"
,"32348986",,,,,"dysphagia",,"68.9 %","%",1,"MSA"
,"32348986",,,,,"stridor",,"42.6 %","%",1,"MSA"
,"32367182",,,,,"mild cognitive impairment",,"47 %","%",1,"MSA"
,"32367182",,,,,"moderate cortical tau pathology three",,"20.8 %","%",1,"MSA"
,"32367182",,,,,"moderate ci",,"14.5 %","%",1,"MSA"
,"32367182",,,,,"free alzheimer type lesions",,"77.1 %","%",1,"MSA"
,"32367182",,,,,"controls",,"42 %","%",1,"MSA"
,"32367182",,,,,"lewy pathology",,"22.9 %","%",1,"MSA"
,"32367182",,,,,"lewy pathology msa cohort",,"8.4 %","%",1,"MSA"
,"32367182",,,,,"msa patients",,"35.3 %","%",1,"MSA"
,"32380911",,,,,"parkinsonism hc",,"91.78 %","%",1,"MSA"
,"32380911",,,,,"pd hc",,"91.18 %","%",1,"MSA"
,"32380911",,,,,"psp hc",,"96.05 %","%",1,"MSA"
,"32380911",,,,,"psp pd",,"70.24 %","%",1,"MSA"
,"32380911",,,,,"msa",,"72.73 %","%",1,"MSA"
,"32516630",,,,,"supine hypertension",,"67 %","%",1,"MSA"
,"32546656",,,,,"paf",,"24 %","%",1,"MSA"
,"32572488",,,,,"primary progressive patients",,"2.7 %","%",1,"MSA"
,"32572488",,,,,"patients",,"2.1 %","%",1,"MSA"
,"32587707",,,,,"pdyn variants",,"0.1 %","%",1,"MSA"
,"32621533",,,,,"male",,"70 %","%",1,"MSA"
,"32621533",,,,,"male",,"68 %","%",1,"MSA"
,"32621533",,,,,"cerebellar variant type",,"59 %","%",1,"MSA"
,"32621533",,,,,"adpec",,"49 %","%",1,"MSA"
,"32621533",,,,,"msa",,"95 %","%",1,"MSA"
,"32621533",,,,,"msa",,"46 %","%",1,"MSA"
,"32644976",,,,,"p =",,"0 %","%",1,"MSA"
,"32677311",,,,,"male",,"64 %","%",1,"MSA"
,"32677311",,,,,"chf",,"38 %","%",1,"MSA"
,"32754107",,,,,"tremor occurrence rate",,"14.9 %","%",1,"MSA"
,"32754107",,,,,"hor",,"4.5 %","%",1,"MSA"
,"32754107",,,,,"sensitivity harmonic pd diagnosis",,"75.0 %","%",1,"MSA"
,"32754107",,,,,"sensitivity harmonic",,"95.5 %","%",1,"MSA"
,"32754107",,,,,"ppv npv",,"75.9 %","%",1,"MSA"
,"32755074",,,,,"acute cerebral infarction",,"34.62 %","%",1,"MSA"
,"32755074",,,,,"wallerian degeneration",,"30.77 %","%",1,"MSA"
,"32755074",,,,,"multiple system atrophy",,"23.08 %","%",1,"MSA"
,"32755074",,,,,"heroin induced leukoencephalopathy",,"3.85 %","%",1,"MSA"
,"32878826",,,,,"mmd",,"0.4 %","%",1,"MSA"
,"32878826",,,,,"mmd",,"0.5 %","%",1,"MSA"
,"32878826",,,,,"asians",,"1.5 %","%",1,"MSA"
,"32878826",,,,,"asians",,"5.2 %","%",1,"MSA"
,"32882100",,,,,"treated patients developed pd specific antibody response",,"89 %","%",1,"MSA"
,"32882100",,,,,"antibody responder rate",,"58 %","%",1,"MSA"
,"32896712",,,,,"community dwellers",,"16 %","%",1,"MSA"
,"32896712",,,,,"institutionalized patients",,"60 %","%",1,"MSA"
,"32939785",,,,,"cases",,"92 %","%",1,"MSA"
,"32978947",,,,,"converted msa",,"80 %","%",1,"MSA"
,"32978947",,,,,"patients developed pd dlb",,"5.4 %","%",1,"MSA"
,"32978947",,,,,"patients converted msa",,"80.0 %","%",1,"MSA"
,"32978947",,,,,"specificity",,"94.6 %","%",1,"MSA"
,"32984413",,,,,"died prior medical intervention rehabilitative efforts",,"65 %","%",1,"MSA"
,"32984413",,,,,"died rehabilitation",,"35 %","%",1,"MSA"
,"32984413",,,,,"respiratory lesions",,"90 %","%",1,"MSA"
,"32984413",,,,,"capture exertional rhabdomyolysis",,"42 %","%",1,"MSA"
,"32984413",,,,,"gastrointestinal tract pathologies",,"75 %","%",1,"MSA"
,"32984413",,,,,"dental attrition",,"40 %","%",1,"MSA"
,"32984413",,,,,"group animals",,"54 %","%",1,"MSA"
,"32984413",,,,,"lesions",,"20 %","%",1,"MSA"
,"33150438",,,,,"growth hormone deficiency",,"28 %","%",1,"MSA"
,"33150438",,,,,"patients hospitalized due symptomatic hypoglycemia",,"55 %","%",1,"MSA"
,"33150438",,,,,"adrenal glucocorticoid insufficiency",,"22 %","%",1,"MSA"
,"33150438",,,,,"hypothyroidism",,"36 %","%",1,"MSA"
,"33164129",,,,,"displayed postural tremor",,"82.8 %","%",1,"MSA"
,"33164129",,,,,"sensitivity",,"87.9 %","%",1,"MSA"
,"33164129",,,,,"specificity",,"89.2 %","%",1,"MSA"
,"33179436",,,,,"hospital prevalence aps parkinsonism cases",,"20.6 %","%",1,"MSA"
,"33179436",,,,,"newly diagnosed aps cases",,"38.8 %","%",1,"MSA"
,"33179436",,,,,"dementia lewy bodies",,"56.7 %","%",1,"MSA"
,"33179436",,,,,"progressive supranuclear palsy",,"16.2 %","%",1,"MSA"
,"33179436",,,,,"multiple system atrophy",,"14.6 %","%",1,"MSA"
,"33179436",,,,,"corticobasal syndrome",,"12.5 %","%",1,"MSA"
,"33179436",,,,,"parkinsonism",,"50.7 %","%",1,"MSA"
,"33193032",,,,,"attrition bias",,"1.4 %","%",1,"MSA"
,"33193032",,,,,"one vemp test abnormal",,"68 %","%",1,"MSA"
,"33193032",,,,,"vemp tests abnormal",,"83 %","%",1,"MSA"
,"33234871",,,,,"msa",,"18.8 %","%",1,"MSA"
,"33234871",,,,,"msa",,"27.3 %","%",1,"MSA"
,"33234871",,,,,"the frequency coexistence three sleep related symptoms",,"7.3 %","%",1,"MSA"
,"33284860",,,,,"parkinson patients",,"77 %","%",1,"MSA"
,"33284860",,,,,"patients dementia lewy bodies multiple system atrophy",,"89 %","%",1,"MSA"
,"33284860",,,,,"progressive supranuclear palsy corticobasal degeneration",,"15 %","%",1,"MSA"
,"33372862",,,,,"antagonistic muscles flexion extension elbow",,"22.3 %","%",1,"MSA"
,"33372862",,,,,"wrist",,"11.9 %","%",1,"MSA"
,"33372862",,,,,"fingers",,"23.9 %","%",1,"MSA"
,"33372862",,,,,"ankle",,"18.2 %","%",1,"MSA"
,"33372862",,,,,"toes",,"14.7 %","%",1,"MSA"
,"33401147",,,,,"sighs",,"12 %","%",1,"MSA"
,"33401147",,,,,"sighs",,"45 %","%",1,"MSA"
,"33401147",,,,,"sighs pd predominantly hypopneas",,"29 %","%",1,"MSA"
,"33495376",,,,,"prevalence rfc disease",,"67 %","%",1,"MSA"
,"33495376",,,,,"unselected cohort b",,"14 %","%",1,"MSA"
,"33495376",,,,,"clinical canvas",,"68 %","%",1,"MSA"
,"33495376",,,,,"rfc disease",,"90 %","%",1,"MSA"
,"33495376",,,,,"rfc positive patients mostly multisystemic",,"69 %","%",1,"MSA"
,"33495376",,,,,"dysautonomia",,"62 %","%",1,"MSA"
,"33495376",,,,,"bradykinesia",,"28 %","%",1,"MSA"
,"33495376",,,,,"postural instability",,"49 %","%",1,"MSA"
,"33495376",,,,,"slow vertical saccades",,"17 %","%",1,"MSA"
,"33495376",,,,,"chorea dystonia",,"11 %","%",1,"MSA"
,"33495376",,,,,"progression",,"50 %","%",1,"MSA"
,"33517029",,,,,"gaze evoked nystagmus",,"35,7 %","%",1,"MSA"
,"33517229",,,,,"plc",,"12.7 %","%",1,"MSA"
,"33517229",,,,,"plc survival patients stage msa",,"12.0 %","%",1,"MSA"
,"33517229",,,,,"msa",,"13.2 %","%",1,"MSA"
,"33558361",,,,,"patients diagnosed cerebellar symptoms predominant type msa",,"58.2 %","%",1,"MSA"
,"33558361",,,,,"parkinsonism",,"29.9 %","%",1,"MSA"
,"33558361",,,,,"umsars part ⅳ score",,"53.8 %","%",1,"MSA"
,"33558361",,,,,"levodopa",,"37.5 %","%",1,"MSA"
,"33662165",,,,,"memory disturbance  common fs ad",,"34 %","%",1,"MSA"
,"33662165",,,,,"ftld",,"19 %","%",1,"MSA"
,"33662165",,,,,"lbd",,"26 %","%",1,"MSA"
,"33662165",,,,,"memory disturbance  common fs ad",,"35 %","%",1,"MSA"
,"33662165",,,,,"msa",,"27 %","%",1,"MSA"
,"33662165",,,,,"cbd",,"20 %","%",1,"MSA"
,"33662165",,,,,"memory disturbance",,"79.0 %","%",1,"MSA"
,"33662165",,,,,"aphasia",,"97.2 %","%",1,"MSA"
,"33662165",,,,,"personality changes",,"96.0 %","%",1,"MSA"
,"33662165",,,,,"lbd",,"54.6 %","%",1,"MSA"
,"33662165",,,,,"lbd",,"97.3 %","%",1,"MSA"
,"33662165",,,,,"coordination disturbance msa",,"59.4 %","%",1,"MSA"
,"33662165",,,,,"dysarthria ftld",,"73.0 %","%",1,"MSA"
,"33666721",,,,,"patients canvas phenotype",,"78 %","%",1,"MSA"
,"33856546",,,,,"anti nae antibody rates",,"31.9 %","%",1,"MSA"
,"33856546",,,,,"positive anti nae antibody rates",,"10.3 %","%",1,"MSA"
,"33856546",,,,,"positive anti nae antibody rates",,"50.0 %","%",1,"MSA"
,"33856546",,,,,"positive anti nae antibody rates",,"11.1 %","%",1,"MSA"
,"33910524",,,,,"camptocormia",,"19.2 %","%",1,"MSA"
,"34056874",,,,,"multiple step pattern",,"68.6 %","%",1,"MSA"
,"34056874",,,,,"multiple step pattern",,"65.2 %","%",1,"MSA"
,"34056874",,,,,"<",,"2.5 %","%",1,"MSA"
,"34056874",,,,,"abnormal saccade",,"63.6 %","%",1,"MSA"
,"34056874",,,,,"abnormal saccade",,"7.5 %","%",1,"MSA"
,"34056874",,,,,"saccade intrusions",,"28.1 %","%",1,"MSA"
,"34056874",,,,,"msa patients",,"51.5 %","%",1,"MSA"
,"34056874",,,,,"gaze evoked nystagmus",,"24.2 %","%",1,"MSA"
,"34056874",,,,,"square wave jerks",,"6.1 %","%",1,"MSA"
,"34132390",,,,,"fatigue",,"28.7 %","%",1,"MSA"
,"34134116",,,,,"clinical rbd",,"70.4 %","%",1,"MSA"
,"34196429",,,,,"vapb negative neurons pontine nucleus",,"13.6 %","%",1,"MSA"
,"34196429",,,,,"vapb negative neurons",,"0.6 %","%",1,"MSA"
,"34196429",,,,,"cytoplasmic inclusions",,"42.2 %","%",1,"MSA"
,"34196429",,,,,"vapb positive neurons",,"3.6 %","%",1,"MSA"
,"34196429",,,,,"oligodendrocytes",,"67.2 %","%",1,"MSA"
,"34196429",,,,,"neurons",,"51.1 %","%",1,"MSA"
,"34209067",,,,,"msa",,"87.5 %","%",1,"MSA"
,"34209067",,,,,"psp patients complained least one neuropathic symptom",,"66.7 %","%",1,"MSA"
,"34209067",,,,,"msa psp patients",,"50.0 %","%",1,"MSA"
,"34255887",,,,,"severe ncis",,"8.2 %","%",1,"MSA"
,"34316623",,,,,"onset events",,"64 %","%",1,"MSA"
,"34316623",,,,,"vfmi sa mv dysphagia surgeries",,"49 %","%",1,"MSA"
,"34316623",,,,,"medical study",,"68 %","%",1,"MSA"
,"34316623",,,,,"na",,"22 %","%",1,"MSA"
,"34316623",,,,,"twenty seven patients",,"24 %","%",1,"MSA"
,"3435079",,,,,"postganglionic sudomotor failure",,"50 %","%",1,"MSA"
,"3435079",,,,,"paf msa patients",,"69 %","%",1,"MSA"
,"3435079",,,,,"paf msa patients",,"66 %","%",1,"MSA"
,"3435079",,,,,"vagal abnormalities",,"77 %","%",1,"MSA"
,"3435079",,,,,"paf msa patients",,"81 %","%",1,"MSA"
,"34413766",,,,,"specificity",,"79.2 %","%",1,"MSA"
,"34472165",,,,,"seizure prevalence",,"31.3 %","%",1,"MSA"
,"34472165",,,,,"cbd",,"20.0 %","%",1,"MSA"
,"34472165",,,,,"lbd",,"12.6 %","%",1,"MSA"
,"34472165",,,,,"ftld",,"11.3 %","%",1,"MSA"
,"34472165",,,,,"msa",,"8.3 %","%",1,"MSA"
,"34472165",,,,,"psp",,"7.5 %","%",1,"MSA"
,"34472165",,,,,"patients without cognitive first symptoms",,"11.0 %","%",1,"MSA"
,"34472165",,,,,"patients without motor first symptoms",,"20.5 %","%",1,"MSA"
,"34481140",,,,,"msa patients",,"96.2 %","%",1,"MSA"
,"34481140",,,,,"msa patients",,"80 %","%",1,"MSA"
,"34481140",,,,,"msa patients",,"60.4 %","%",1,"MSA"
,"34481140",,,,,"msa p patient",,"98.1 %","%",1,"MSA"
,"34481140",,,,,"patients msa",,"69.8 %","%",1,"MSA"
,"34481140",,,,,"sensitivity",,"95.0 %","%",1,"MSA"
,"34498198",,,,,"fxtas",,"0.3 %","%",1,"MSA"
,"34506665",,,,,"balanced accuracy",,"74.2 %","%",1,"MSA"
,"34506665",,,,,"specificity",,"75.0 %","%",1,"MSA"
,"34506665",,,,,"sensitivity",,"73.3 %","%",1,"MSA"
,"34663646",,,,,"fatigue",,"60.3 %","%",1,"MSA"
,"34663646",,,,,"fatigue",,"55.1 %","%",1,"MSA"
,"34663646",,,,,"fatigue",,"64.9 %","%",1,"MSA"
,"34718269",,,,,"anxiety",,"22.1 %","%",1,"MSA"
,"34718269",,,,,"anxiety",,"13 %","%",1,"MSA"
,"34718269",,,,,"anxiety levels",,"34.2 %","%",1,"MSA"
,"34718269",,,,,"depression",,"50 %","%",1,"MSA"
,"34718269",,,,,"depression",,"58.9 %","%",1,"MSA"
,"34718269",,,,,"depression",,"97.3 %","%",1,"MSA"
,"34764851",,,,,"hypertension",,"20.2 %","%",1,"MSA"
,"34764851",,,,,"diabetes mellitus",,"10.3 %","%",1,"MSA"
,"34764851",,,,,"hyperlipidemia",,"10.2 %","%",1,"MSA"
,"34764851",,,,,"obesity",,"9.6 %","%",1,"MSA"
,"34764851",,,,,"msa predominant cerebellar ataxia",,"44.9 %","%",1,"MSA"
,"34845661",,,,,"sporadic cerebellar ataxia",,"3.7 %","%",1,"MSA"
,"34987378",,,,,"msa",,"25.3 %","%",1,"MSA"
,"3504548",,,,,"transmission body movement",,"40 %","%",1,"MSA"
,"35087473",,,,,"males",,"60.6 %","%",1,"MSA"
,"35087473",,,,,"epworth sleepiness scale score >",,"27.3 %","%",1,"MSA"
,"35111522",,,,,"neurodegenerative disorders",,"24.6 %","%",1,"MSA"
,"35111522",,,,,"incidence",,"68.1 %","%",1,"MSA"
,"35111522",,,,,"α synucleinopathies",,"85.7 %","%",1,"MSA"
,"35275559",,,,,"cardiac α syn pathology",,"82 %","%",1,"MSA"
,"35275559",,,,,"cardiac α syn pathology",,"0 %","%",1,"MSA"
,"35350553",,,,,"patients parkinson disease",,"43.4 %","%",1,"MSA"
,"35350553",,,,,"patients multiple system atrophy",,"23.1 %","%",1,"MSA"
,"35350553",,,,,"patients progressive supranuclear palsy",,"77.8 %","%",1,"MSA"
,"35350553",,,,,"dementia",,"54 %","%",1,"MSA"
,"35350553",,,,,"progressive supranuclear palsy",,"71 %","%",1,"MSA"
,"35350553",,,,,"dementia",,"9 %","%",1,"MSA"
,"35350553",,,,,"mild cognitive impairment",,"85 %","%",1,"MSA"
,"35434388",,,,,"misdiagnosis",,"25 %","%",1,"MSA"
,"35434388",,,,,"subjects",,"91 %","%",1,"MSA"
,"35434388",,,,,"pd",,"90 %","%",1,"MSA"
,"35434388",,,,,"pps",,"93 %","%",1,"MSA"
,"35462702",,,,,"fog",,"65.93 %","%",1,"MSA"
,"35585902",,,,,"change diagnosis time",,"94 %","%",1,"MSA"
,"35585902",,,,,"n =  change diagnosis",,"6 %","%",1,"MSA"
,"35585902",,,,,"pd ⟷ drug induced parkinsonism",,"27.1 %","%",1,"MSA"
,"35585902",,,,,"progressive supranuclear palsy",,"20.0 %","%",1,"MSA"
,"35585902",,,,,"na pd ⟷ lewy body dementia",,"18.8 %","%",1,"MSA"
,"35585902",,,,,"na pd ⟷ vascular parkinsonism",,"16.5 %","%",1,"MSA"
,"35585902",,,,,"two diagnoses",,"9.4 %","%",1,"MSA"
,"35585902",,,,,"na",,"4.7 %","%",1,"MSA"
,"35585902",,,,,"parkinsonism diseases",,"36.5 %","%",1,"MSA"
,"35585902",,,,,"multiple switches",,"31.8 %","%",1,"MSA"
,"35586204",,,,,"female",,"42 %","%",1,"MSA"
,"35586204",,,,,"glycemia",,"18.18 %","%",1,"MSA"
,"35586204",,,,,"ifg",,"50.6 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"93.3 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"37.7 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"51.1 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"73.3 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"71.1 %","%",1,"MSA"
,"35809545",,,,,"abnormal eye movements",,"37.8 %","%",1,"MSA"
,"35852957",,,,,"parkinsons disease pd patients",,"0.30 %","%",1,"MSA"
,"35852957",,,,,"low penetrance htt repeat expansions",,"0.19 %","%",1,"MSA"
,"35852957",,,,,"htt intermediate alleles",,"3.9 %","%",1,"MSA"
,"35968298",,,,,"efficacy drug treatment",,"64.5 %","%",1,"MSA"
,"35972621",,,,,"frailty sarcopenia",,"48.57 %","%",1,"MSA"
,"35972621",,,,,"multiple system atrophy",,"35.71 %","%",1,"MSA"
,"35972621",,,,,"progressive supranuclear palsy",,"51.09 %","%",1,"MSA"
,"35972621",,,,,"progressive supranuclear palsy",,"39.13 %","%",1,"MSA"
,"35974129",,,,,"median lifespan",,"14 %","%",1,"MSA"
,"35974129",,,,,"age",,"9 %","%",1,"MSA"
,"36036411",,,,,"sca",,"1.5 %","%",1,"MSA"
,"36057079",,,,,"neuropil antibodies",,"17.9 %","%",1,"MSA"
,"36057079",,,,,"msa c",,"3.3 %","%",1,"MSA"
,"36057079",,,,,"healthy subjects",,"0 %","%",1,"MSA"
,"36247899",,,,,"female sexual sensation",,"55 %","%",1,"MSA"
,"36247899",,,,,"forgetfulness",,"60 %","%",1,"MSA"
,"36247899",,,,,"pseudobulbar affect",,"37 %","%",1,"MSA"
,"36247899",,,,,"olfactory changes",,"36 %","%",1,"MSA"
,"36247899",,,,,"visual hallucinations",,"21 %","%",1,"MSA"
,"36263296",,,,,"cmct abnormalities found upper limbs",,"44 %","%",1,"MSA"
,"36263296",,,,,"msa patients",,"7 %","%",1,"MSA"
,"36263296",,,,,"cmct abnormalities limbs",,"55 %","%",1,"MSA"
,"36263296",,,,,"msa",,"20 %","%",1,"MSA"
,"36303452",,,,,"four cases",,"0.21 %","%",1,"MSA"
,"36336940",,,,,"cognitive impairment",,"37 %","%",1,"MSA"
,"36336940",,,,,"dementia",,"11 %","%",1,"MSA"
,"36336940",,,,,"clinically diagnosed msa",,"14 %","%",1,"MSA"
,"36348076",,,,,"depression",,"43 %","%",1,"MSA"
,"36526431",,,,,"dementia",,"14 %","%",1,"MSA"
,"36526431",,,,,"cognitive impairment patients msa",,"41 %","%",1,"MSA"
,"36540145",,,,,"male",,"60 %","%",1,"MSA"
,"36540145",,,,,"the place death",,"45.9 %","%",1,"MSA"
,"36540145",,,,,"long term care",,"36.3 %","%",1,"MSA"
,"36540145",,,,,"home",,"7.9 %","%",1,"MSA"
,"36540145",,,,,"residential hospice",,"4.0 %","%",1,"MSA"
,"36540145",,,,,"most  > ed visit",,"64.2 %","%",1,"MSA"
,"36540145",,,,,"> emergency department visits",,"14.4 %","%",1,"MSA"
,"36540145",,,,,"spent > days hospital",,"23.3 %","%",1,"MSA"
,"36540145",,,,,"few  admitted icu",,"2.6 %","%",1,"MSA"
,"36540145",,,,,"accessed outpatient neurologist specialist palliative care services",,"37.2 %","%",1,"MSA"
,"36540145",,,,,"accessed outpatient neurologist specialist palliative care services",,"8.8 %","%",1,"MSA"
,"36585649",,,,,"vva",,"34.8 %","%",1,"MSA"
,"36585649",,,,,"urinary incontinence",,"47.5 %","%",1,"MSA"
,"36585649",,,,,"pop highly prevalent anterior vaginal wall",,"38.9 %","%",1,"MSA"
,"36585649",,,,,"posterior vaginal wall",,"25.3 %","%",1,"MSA"
,"36585649",,,,,"uterine",,"22.2 %","%",1,"MSA"
,"36645025",,,,,"rituximab",,"41.7 %","%",1,"MSA"
,"36645025",,,,,"grade fazekas",,"0 %","%",1,"MSA"
,"36668680",,,,,"sudden cardiac death",,"51.3 %","%",1,"MSA"
,"36668680",,,,,"sudden cardiac death",,"22.6 %","%",1,"MSA"
,"36698891",,,,,"cop position trajectory",,"95 %","%",1,"MSA"
,"36751940",,,,,"moca",,"38 %","%",1,"MSA"
,"36751940",,,,,"motor function alternate tap test",,"48 %","%",1,"MSA"
,"36751940",,,,,"bsit",,"57 %","%",1,"MSA"
,"36751940",,,,,"autonomic function",,"38.8 %","%",1,"MSA"
,"36751940",,,,,"anxiety depression",,"39.3 %","%",1,"MSA"
,"36751940",,,,,"anxiety depression",,"31 %","%",1,"MSA"
,"36756345",,,,,"patients msa  nms",,"85.2 %","%",1,"MSA"
,"36756345",,,,,"pd",,"28.7 %","%",1,"MSA"
,"36756345",,,,,"psp",,"33.3 %","%",1,"MSA"
,"36864385",,,,,"males",,"92.3 %","%",1,"MSA"
,"36864385",,,,,"females",,"86.7 %","%",1,"MSA"
,"36864385",,,,,"specificity",,"72.7 %","%",1,"MSA"
,"36864385",,,,,"females",,"90 %","%",1,"MSA"
,"36864661",,,,,"prevalence",,"5 %","%",1,"MSA"
,"36864661",,,,,"amyotrophic lateral sclerosis",,"56 %","%",1,"MSA"
,"36864661",,,,,"multiple system atrophy",,"65 %","%",1,"MSA"
,"36864661",,,,,"alzheimers disease",,"1 %","%",1,"MSA"
,"36864661",,,,,"alzheimers disease",,"58 %","%",1,"MSA"
,"36864661",,,,,"lewy body disease",,"37 %","%",1,"MSA"
,"36916668",,,,,"familial cases",,"10 %","%",1,"MSA"
,"36916668",,,,,"mlpa",,"9 %","%",1,"MSA"
,"36916668",,,,,"lrrk gs mutations",,"4.8 %","%",1,"MSA"
,"36916668",,,,,"prkn mutations",,"3.4 %","%",1,"MSA"
,"36916668",,,,,"snca locus duplications",,"0.9 %","%",1,"MSA"
,"36951957",,,,,"ckd",,"40 %","%",1,"MSA"
,"36971870",,,,,"pd",,"42.9 %","%",1,"MSA"
,"36971870",,,,,"pd",,"59.8 %","%",1,"MSA"
,"36971870",,,,,"atx",,"24.1 %","%",1,"MSA"
,"36971870",,,,,"atx",,"14.3 %","%",1,"MSA"
,"37077676",,,,,"diagnoses",,"26 %","%",1,"MSA"
,"37077676",,,,,"classification accuracy",,"85.18 %","%",1,"MSA"
,"37095443",,,,,"mm",,"1.11 %","%",1,"MSA"
,"37095443",,,,,"eyes",,"0.4 %","%",1,"MSA"
,"37178348",,,,,"breast cancer",,"0.83 %","%",1,"MSA"
,"37178348",,,,,"controls",,"0.67 %","%",1,"MSA"
,"37178348",,,,,"us population",,"2.0 %","%",1,"MSA"
,"37190547",,,,,"msa mci",,"51 %","%",1,"MSA"
,"37315251",,,,,"cerebellar ataxia hiv infection",,"1.3 %","%",1,"MSA"
,"37316556",,,,,"excessive daytime sleepiness",,"94.3 %","%",1,"MSA"
,"37316556",,,,,"pd",,"33.9 %","%",1,"MSA"
,"37316556",,,,,"msa",,"79.7 %","%",1,"MSA"
,"37316556",,,,,"pd",,"79.9 %","%",1,"MSA"
,"37316556",,,,,"psp",,"49.3 %","%",1,"MSA"
,"37316556",,,,,"dlb",,"42 %","%",1,"MSA"
,"37316556",,,,,"cbd",,"53.8 %","%",1,"MSA"
,"37316556",,,,,"psp",,"56 %","%",1,"MSA"
,"37316556",,,,,"msa",,"48 %","%",1,"MSA"
,"37316556",,,,,"dlb",,"44 %","%",1,"MSA"
,"37316556",,,,,"cbd",,"43 %","%",1,"MSA"
,"37351425",,,,,"msa",,"38.7 %","%",1,"MSA"
,"37360344",,,,,"constipation",,"39.3 %","%",1,"MSA"
,"37360344",,,,,"onset motor symptoms",,"59.8 %","%",1,"MSA"
,"37422580",,,,,"patients",,"21 %","%",1,"MSA"
,"37422580",,,,,"patients met enh sh criteria",,"9 %","%",1,"MSA"
,"37422580",,,,,"sh",,"39 %","%",1,"MSA"
,"37422580",,,,,"enh",,"90 %","%",1,"MSA"
,"37422580",,,,,"daytime carbon dioxide pressure arterial blood ≤ mmhg",,"13 %","%",1,"MSA"
,"37610447",,,,,"japanese ca patients",,"5 %","%",1,"MSA"
,"37610447",,,,,"positivity rate",,"30 %","%",1,"MSA"
,"37647745",,,,,"oxyhemoglobin desaturation index",,"4 %","%",1,"MSA"
,"37647745",,,,,"pei  odi",,"46 %","%",1,"MSA"
,"6306310",,,,,"items",,"40 %","%",1,"MSA"
,"6371591",,,,,"india",,"2.8 %","%",1,"MSA"
,"6371591",,,,,"mexico",,"39 %","%",1,"MSA"
,"6371591",,,,,"los angeles",,"71 %","%",1,"MSA"
,"6495169",,,,,"bilateral monocular blindness",,"63 %","%",1,"MSA"
,"6495169",,,,,"damage optic nerve",,"35 %","%",1,"MSA"
,"7575219",,,,,"response rate",,"82.5 %","%",1,"MSA"
,"7575219",,,,,"parkinsons disease",,"0.71 %","%",1,"MSA"
,"7575219",,,,,"four inhabitants",,"0.41 %","%",1,"MSA"
,"7575219",,,,,"vascular ps",,"0.20 %","%",1,"MSA"
,"7575219",,,,,"multiple system atrophy",,"0.31 %","%",1,"MSA"
,"7575219",,,,,"fahrs disease",,"0.10 %","%",1,"MSA"
,"7745413",,,,,"abnormal nerve conduction studies",,"40 %","%",1,"MSA"
,"7745413",,,,,"mixed sensorimotor axonal neuropathy",,"17.5 %","%",1,"MSA"
,"7745413",,,,,"abnormal skeletal muscle emg",,"22.5 %","%",1,"MSA"
,"7823405",,,,,"patients whole motor cortex",,"50.9 %","%",1,"MSA"
,"7823405",,,,,"either whole partial motor cortex",,"88.7 %","%",1,"MSA"
,"7823405",,,,,"occipital cortex",,"47.2 %","%",1,"MSA"
,"7823405",,,,,"sensory cortex",,"20.8 %","%",1,"MSA"
,"7899721",,,,,"atrophy nerve fiber ganglion cell layers",,"73 %","%",1,"MSA"
,"7899721",,,,,"choroiditis",,"11.5 %","%",1,"MSA"
,"7899721",,,,,"retinal phlebitis",,"20 %","%",1,"MSA"
,"8158173",,,,,"cases",,"80 %","%",1,"MSA"
,"8158173",,,,,"typical atypical parkinsonian syndromes",,"64 %","%",1,"MSA"
,"8158173",,,,,"typical atypical parkinsonian syndromes",,"69 %","%",1,"MSA"
,"8158173",,,,,"given diagnosis sro",,"70 %","%",1,"MSA"
,"8158173",,,,,"cases",,"60 %","%",1,"MSA"
,"8158173",,,,,"cases",,"90 %","%",1,"MSA"
,"8174325",,,,,"patients subtype scd",,"34.4 %","%",1,"MSA"
,"8174325",,,,,"menzel type hereditary cerebellar ataxia",,"12.6 %","%",1,"MSA"
,"8174325",,,,,"holmes type hereditary cerebellar ataxia",,"7.5 %","%",1,"MSA"
,"8174325",,,,,"shy drager syndrome",,"7.0 %","%",1,"MSA"
,"8174325",,,,,"hereditary spastic paraplegia",,"3.9 %","%",1,"MSA"
,"8174325",,,,,"na",,"2.5 %","%",1,"MSA"
,"8174325",,,,,"na",,"2.4 %","%",1,"MSA"
,"8174325",,,,,"na",,"2.0 %","%",1,"MSA"
,"8174325",,,,,"order",,"1.5 %","%",1,"MSA"
,"8247316",,,,,"hereditary monogenic disorders",,"30 %","%",1,"MSA"
,"8247316",,,,,"total neurological admissions",,"1.8 %","%",1,"MSA"
,"8247316",,,,,"+",,"7 %","%",1,"MSA"
,"8272177",,,,,"sensitivity",,"98 %","%",1,"MSA"
,"8272177",,,,,"specificity",,"89 %","%",1,"MSA"
,"8272177",,,,,"years old",,"1.5 %","%",1,"MSA"
,"8272177",,,,,"females",,"50.2 %","%",1,"MSA"
,"8272177",,,,,"males",,"49.8 %","%",1,"MSA"
,"8272177",,,,,"consanguineous marriages",,"54.6 %","%",1,"MSA"
,"8460965",,,,,"patients normal ssrs orthostatic hypotension",,"8 %","%",1,"MSA"
,"8677029",,,,,"patients onset sma",,"95 %","%",1,"MSA"
,"8748604",,,,,"patients",,"73 %","%",1,"MSA"
,"8748604",,,,,"urinary symptoms",,"37 %to 71 %","%",1,"MSA"
,"8748604",,,,,"urinary symptoms",,"71 %","%",1,"MSA"
,"8748604",,,,,"cardiopressor adaptability",,"15 %","%",1,"MSA"
,"8750553",,,,,"pain reported  msa patients",,"47 %","%",1,"MSA"
,"8750553",,,,,"rheumatic",,"64 %","%",1,"MSA"
,"8750553",,,,,"sensory",,"28 %","%",1,"MSA"
,"8750553",,,,,"dystonic",,"21 %","%",1,"MSA"
,"8750553",,,,,"levodopa related",,"16 %","%",1,"MSA"
,"8750553",,,,,"mixed pain syndrome",,"19 %","%",1,"MSA"
,"8750553",,,,,"disease onset",,"30 %","%",1,"MSA"
,"8949386",,,,,"hr hf",,"3 %","%",1,"MSA"
,"8949386",,,,,"na",,"1 %","%",1,"MSA"
,"8949386",,,,,"insulin plasma levels",,"80 %","%",1,"MSA"
,"9065918",,,,,"frequency mutations",,"4.5 %","%",1,"MSA"
,"9159723",,,,,"parkinsonism",,"46 %","%",1,"MSA"
,"9159723",,,,,"vascular parkinsonism",,"57 %","%",1,"MSA"
,"9159723",,,,,"normal pressure hydrocephalus",,"56 %","%",1,"MSA"
,"9240187",,,,,"urinary symptoms",,"60 %","%",1,"MSA"
,"9240187",,,,,"ipd neurological diagnosis preceded onset urogenital symptoms",,"94 %","%",1,"MSA"
,"9240187",,,,,"troublesome urinary incontinence",,"73 %","%",1,"MSA"
,"9240187",,,,,"ipd",,"85 %","%",1,"MSA"
,"9240187",,,,,"patients msa",,"66 %","%",1,"MSA"
,"9240187",,,,,"patients ipd",,"16 %","%",1,"MSA"
,"9240187",,,,,"erectile dysfunction",,"93 %","%",1,"MSA"
,"9240187",,,,,"complaint preceded diagnosis msa",,"48 %","%",1,"MSA"
,"9284194",,,,,"symptoms  patients",,"70 %","%",1,"MSA"
,"9311353",,,,,"ht",,"20.6 %","%",1,"MSA"
,"9311353",,,,,"levodopa responsive parkinsonism",,"16.6 %","%",1,"MSA"
,"9311353",,,,,"presymptomatic ht seen ps dementia",,"13.3 %","%",1,"MSA"
,"9311353",,,,,"na",,"19.3 %","%",1,"MSA"
,"9311353",,,,,"olivopontocerebellar atrophy",,"18 %","%",1,"MSA"
,"9311353",,,,,"corticobasal ganglionic degeneration",,"33.3 %","%",1,"MSA"
,"9311353",,,,,"drug induced ps",,"23.1 %","%",1,"MSA"
,"9311353",,,,,"parkinson disease",,"39.5 %","%",1,"MSA"
,"9311353",,,,,"progressive supranuclear palsy",,"81.0 %","%",1,"MSA"
,"9311353",,,,,"small vessel disease",,"50 %","%",1,"MSA"
,"9369256",,,,,"hypertension",,"63 %","%",1,"MSA"
,"9369256",,,,,"hypertension",,"52 %","%",1,"MSA"
,"9613802",,,,,"na",,"41 %","%",1,"MSA"
,"9698723",,,,,"patients pa evaluated movement disorders clinics",,"72 %","%",1,"MSA"
,"9698723",,,,,"pd",,"68.9 %","%",1,"MSA"
,"9698723",,,,,"drug induced pa",,"13.3 %","%",1,"MSA"
,"9698723",,,,,"vascular pa",,"4.7 %","%",1,"MSA"
,"9698723",,,,,"progressive supranuclear palsy",,"2 %","%",1,"MSA"
,"9698723",,,,,"multiple system atrophy",,"1.8 %","%",1,"MSA"
,"9698723",,,,,"others",,"9.7 %","%",1,"MSA"
,"9698723",,,,,"pa patients",,"70 %","%",1,"MSA"
,"9771493",,,,,"patients paf",,"93 %","%",1,"MSA"
,"9771493",,,,,"patients msa",,"51 %","%",1,"MSA"
,"9836034",,,,,"eeg power",,"90 %","%",1,"MSA"
,"9836034",,,,,"dose vecuronium",,"50 %","%",1,"MSA"
